<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Genet</journal-id><journal-id journal-id-type="iso-abbrev">Front Genet</journal-id><journal-id journal-id-type="pmc-domain-id">1681</journal-id><journal-id journal-id-type="pmc-domain">frontgene</journal-id><journal-id journal-id-type="publisher-id">Front. Genet.</journal-id><journal-title-group><journal-title>Frontiers in Genetics</journal-title></journal-title-group><issn pub-type="epub">1664-8021</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7921795</article-id><article-id pub-id-type="pmcid-ver">PMC7921795.1</article-id><article-id pub-id-type="pmcaid">7921795</article-id><article-id pub-id-type="pmcaiid">7921795</article-id><article-id pub-id-type="pmid">33664772</article-id><article-id pub-id-type="doi">10.3389/fgene.2021.637362</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Genetics</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Majumdar</surname><given-names initials="S">Sreyashi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1217495/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Verma</surname><given-names initials="R">Rohit</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1160678/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saha</surname><given-names initials="A">Avishek</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1219191/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhattacharyya</surname><given-names initials="P">Parthasarathi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maji</surname><given-names initials="P">Pradipta</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1219422/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Surjit</surname><given-names initials="M">Milan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/455596/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kundu</surname><given-names initials="M">Manikuntala</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/945126/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Basu</surname><given-names initials="J">Joyoti</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/73639/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saha</surname><given-names initials="S">Sudipto</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/12286/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Division of Bioinformatics, Bose Institute</institution>, <addr-line>Kolkata</addr-line>, <country>India</country></aff><aff id="aff2"><sup>2</sup><institution>Virology Laboratory, Vaccine and Infectious Disease Research Centre, Translational Health Science and Technology Institute, NCR Biotech Science Cluster</institution>, <addr-line>Faridabad</addr-line>, <country>India</country></aff><aff id="aff3"><sup>3</sup><institution>Ubiquitous Analytical Techniques, CSIR-Central Scientific Instruments Organisation</institution>, <addr-line>Chandigarh</addr-line>, <country>India</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Respiratory Medicine, Institute of Pulmocare and Research</institution>, <addr-line>Kolkata</addr-line>, <country>India</country></aff><aff id="aff5"><sup>5</sup><institution>Biomedical Imaging and Bioinformatics Lab, Machine Intelligence Unit, Indian Statistical Institute</institution>, <addr-line>Kolkata</addr-line>, <country>India</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Chemistry, Bose Institute</institution>, <addr-line>Kolkata</addr-line>, <country>India</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Indrajit Saha, National Institute of Technical Teachers&#8217; Training and Research, India</p></fn><fn fn-type="edited-by"><p>Reviewed by: Michael Poidinger, Murdoch Childrens Research Institute, Royal Children&#8217;s Hospital, Australia; Balaji Banoth, St. Jude Children&#8217;s Research Hospital, United States; Ashok Sharma, Augusta University, United States</p></fn><corresp id="c001">*Correspondence: Sudipto Saha, <email>ssaha4@jcbose.ac.in</email>; <email>ssaha4@gmail.com</email></corresp><fn fn-type="other" id="fn004"><p>This article was submitted to Computational Genomics, a section of the journal Frontiers in Genetics</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">374679</issue-id><elocation-id>637362</elocation-id><history><date date-type="received"><day>03</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>19</day><month>1</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>02</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>03</day><month>03</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-06 17:25:35.700"><day>06</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2021 Majumdar, Verma, Saha, Bhattacharyya, Maji, Surjit, Kundu, Basu and Saha.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Majumdar, Verma, Saha, Bhattacharyya, Maji, Surjit, Kundu, Basu and Saha</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fgene-12-637362.pdf"/><abstract><p>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus induced disease-2019 (COVID-19), is a type of common cold virus responsible for a global pandemic which requires immediate measures for its containment. India has the world&#8217;s largest population aged between 10 and 40 years. At the same time, India has a large number of individuals with diabetes, hypertension and kidney diseases, who are at a high risk of developing COVID-19. A vaccine against the SARS-CoV-2, may offer immediate protection from the causative agent of COVID-19, however, the protective memory may be short-lived. Even if vaccination is broadly successful in the world, India has a large and diverse population with over one-third being below the poverty line. Therefore, the success of a vaccine, even when one becomes available, is uncertain, making it necessary to focus on alternate approaches of tackling the disease. In this review, we discuss the differences in COVID-19 death/infection ratio between urban and rural India; and the probable role of the immune system, co-morbidities and associated nutritional status in dictating the death rate of COVID-19 patients in rural and urban India. Also, we focus on strategies for developing masks, vaccines, diagnostics and the role of drugs targeting host-virus protein-protein interactions in enhancing host immunity. We also discuss India&#8217;s strengths including the resources of medicinal plants, good food habits and the role of information technology in combating COVID-19. We focus on the Government of India&#8217;s measures and strategies for creating awareness in the containment of COVID-19 infection across the country.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>genetic variations</kwd><kwd>host immuno-modulation</kwd><kwd>repurposed drugs</kwd><kwd>vaccines</kwd><kwd>medicinal plants</kwd><kwd>CT scans</kwd><kwd>artificial intelligence</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Bose Institute<named-content content-type="fundref-id">10.13039/501100015655</named-content></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="5"/><equation-count count="0"/><ref-count count="177"/><page-count count="21"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Coronavirus disease 2019 (COVID-19) outbreak, caused by the novel coronavirus (SARS-CoV-2) has emerged as a global epidemic and posed serious worldwide public health concerns owing to the contagious nature of the virus and high death rate. Transmission through droplets facilitated its rapid spread and caused panic across the globe. There were 80,776,890 confirmed cases worldwide till December 30, 2020<sup><xref ref-type="fn" rid="footnote1">1</xref></sup>. India has also been largely affected by instances of COVID-19. SARS-CoV-2 viral protein interacts with various host proteins to mediate viral entry and replication in the human host (<xref rid="B74" ref-type="bibr">Khorsand et al., 2020</xref>). Targeting virus and host protein-protein interactions or downstream signaling cascades using novel or repositioned drugs, serves as one of the strategies for COVID-19 therapy. Several drugs such as remdesivir, dexamethasone, hydroxychloroquine, ivermectin, azithromycin, tocalizumab, famotidine, thalidomide have been evaluated in different countries for their efficacy in treating COVID-19 (<xref rid="B112" ref-type="bibr">Omolo et al., 2020</xref>). Convalescent plasma therapy has been recommended by FDA as an alternative therapeutic strategy for severe forms of COVID-19 infection<sup><xref ref-type="fn" rid="footnote2">2</xref></sup>. Vaccination has been considered as the major option for containing the COVID-19 pandemic. Presently, 172 vaccine candidates are in developmental stage, while 63 have entered clinical trials<sup><xref ref-type="fn" rid="footnote3">3</xref></sup>. The Oxford COVID-19 group have clinically proven the safety of the ChAdOx1 nCoV-19 vaccine in triggering humoral and cellular immune response against SARS-CoV-2. The vaccine is presently under the phase 3 trial program across the world (<xref rid="B44" ref-type="bibr">Folegatti et al., 2020</xref>). The phase 3 trials of Covishield, the Oxford vaccine in India have been conducted under the supervision of Serum Institute of India, Pune and the vaccine has been approved for emergency supply and use in India<sup><xref ref-type="fn" rid="footnote4">4</xref></sup><sup>,<xref ref-type="fn" rid="footnote5">5</xref></sup>. COVAXIN has been developed as India&#8217;s first indigenous vaccine by Bharat Biotech in association with Indian Council of Medical Research (ICMR). COVAXIN has currently gone into Phase III clinical trial after successful completion of Phase I and II clinical trials started by Bharat Biotech from July, 2020 onwards<sup><xref ref-type="fn" rid="footnote6">6</xref></sup>. Recently, the Drug Controller General of India (DCGI) has granted emergency approval to COVAXIN in India<sup><xref ref-type="fn" rid="footnote7">7</xref></sup>. The Ministry of Ayush under the Govt. of India has emphasized the importance of exploiting medicinal herbs in the context of COVID-19. Indian indigenous medicinal plants with immune regulating properties have often served to boost immunity and render protection against viral infections (<xref rid="B5" ref-type="bibr">Akram et al., 2018</xref>; <xref rid="B102" ref-type="bibr">Mohanraj et al., 2018</xref>). Besides these, the Govt. of India has adopted certain strategies such as social distancing and extensive lockdown for effective containment of COVID-19 and has launched the artificial intelligence (AI) based mobile application Aarogya Setu to create public awareness.</p><p>Computational bioinformatics and AI have been exploited for better management of COVID-19. Machine learning techniques (MLTs) have been employed for taxonomic and hierarchical classification of SARS-CoV-2 strains (<xref rid="B124" ref-type="bibr">Randhawa et al., 2020</xref>). Computational approaches used in CRISPR based detection systems and neural network for COVID-19 detection have increased diagnostic accuracy (<xref rid="B7" ref-type="bibr">Alimadadi et al., 2020</xref>; <xref rid="B83" ref-type="bibr">Li et al., 2020</xref>). Deep learning technology based on pulmonary CT scan images has successfully allowed differentiation of COVID-19 from other respiratory diseases such as community acquired pneumonia (<xref rid="B83" ref-type="bibr">Li et al., 2020</xref>). Novel text mining based collection of COVID-19 related big data, followed by subsequent analyses using advanced machine learning techniques have enabled real time surveillance of viral epidemiology and live tracking of COVID-19 cases. Access to these digital big data through mobile applications allows potential risk assessment and rapid information dissemination in public for creating social awareness and better mitigation of COVID-19 (<xref rid="B7" ref-type="bibr">Alimadadi et al., 2020</xref>; <xref rid="B17" ref-type="bibr">Bragazzi et al., 2020</xref>; <xref rid="B146" ref-type="bibr">Srinivasa Rao and Vazquez, 2020</xref>; <xref rid="B149" ref-type="bibr">Ting et al., 2020</xref>). Besides, bioinformatics tools and AI are of prime importance in drug discovery and vaccine development for SARS-CoV-2. Repurposing of existing drugs and computation based drug target identification have been extensively performed to accelerate the therapy of COVID-19. In silico docking and deep learning based drug designing have been employed to develop novel drugs against SARS-CoV-2 (<xref rid="B7" ref-type="bibr">Alimadadi et al., 2020</xref>; <xref rid="B17" ref-type="bibr">Bragazzi et al., 2020</xref>; <xref rid="B132" ref-type="bibr">Senior et al., 2020</xref>). A deep learning system Alphafold was designed by Google DeepMind for identification of protein structures linked with COVID-19 that might be valuable for vaccine formulation (<xref rid="B132" ref-type="bibr">Senior et al., 2020</xref>). Vaxign reverse vaccinology tool amalgamated with machine learning has also been used to predict vaccine candidates for COVID-19 (<xref rid="B113" ref-type="bibr">Ong et al., 2020</xref>). B-cell epitopes and MHC Class II epitopes can also be predicted using bioinformatics tools for peptide based vaccine development (<xref rid="B63" ref-type="bibr">Jabbari and Rezaei, 2019</xref>). Potential vaccine adjuvants can also be screened using the AI based program named Search Algorithm for Ligands (SAM) (<xref rid="B4" ref-type="bibr">Ahuja et al., 2020</xref>).</p><p>In a nutshell, this review highlights the current scenario of COVID-19 across India, with special emphasis on death/infection ratio in urban and rural India and disease association with co-morbidities. This review also deals with strains of SARS-CoV-2 circulating in India and the immuno-modulatory action of viral proteins. It discusses the various diagnostic kits, masks and disinfection techniques in use for diagnosing and combating COVID-19. This review further focuses on various approaches that may be followed to tackle the problem of SARS-CoV-2 infection (summarized in <xref ref-type="fig" rid="F1">Figure 1</xref>), including immuno-regulating drugs, drugs targeting host-viral protein-protein interactions, vaccines and Indian herbs and plants with medicinal and immuno-modulating properties. Lastly, it deals with role of AI and various Government strategies adopted in India for addressing the COVID-19 pandemic.</p><fig id="F1" position="float" orientation="portrait"><label>FIGURE 1</label><caption><p>Schematic representation of the possible strategies for modulating the host immune system in order to control SARS-CoV-2 infection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fgene-12-637362-g001.jpg"/></fig></sec><sec id="S2"><title>General Scenario in India</title><sec id="S2.SS1"><title>COVID-19 Infection and Death Rate in States and Union territories (UTs) of India: Association With Lifestyle Habits, Proximity to Airport and Urbanization</title><p>The first case of COVID-19 in India was diagnosed in March, 2020. From that time onwards, there has been rise in the incidence of COVID-19 in India with 2,871 and 101,077 active cases on April 3, 2020 and June 2, 2020 respectively. The number of active cases reached a peak of 1,018,454 on September 17, 2020 followed by a decrease to 528,428 active cases on November 4, 2020 and 258,747 active cases on December 30, 2020 and (as evident from <xref ref-type="fig" rid="F2">Figure 2A</xref>). Till December 30, 2020, there has been a total of 10,267,283 confirmed cases in India with a total of 148,774 deaths<sup><xref ref-type="fn" rid="footnote8">8</xref></sup>. In terms of total number of cases, India occupies the second position after United States and is followed by developed nations such as Brazil, Russia, France, and the United Kingdom (as shown in <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>). The numbers of daily new cases have reduced considerably in December, 2020 as compared to that in September, 2020. There has been a consistent increase in percent recovery from April to December with a minimum recovery rate of 69.06% in April 3, 2020 to a recovery rate of 98.51% on December 30, 2020 (as shown in <xref ref-type="fig" rid="F2">Figure 2B</xref>). Likewise, the death percentage has declined to 1.49% on December 30, 2020 after a surge of 30.94% in April 3, 2020 (see text footnote 71). The decrease in COVID-19 deaths (in terms of death/total confirmed case ratio) across different states of India from June, 2020 to December, 2020 has been tabulated in <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 2</xref>.</p><fig id="F2" position="float" orientation="portrait"><label>FIGURE 2</label><caption><p>Schematic representation of trend of COVID-19 pandemic in India. <bold>(A)</bold> Total no. of active cases in India. <bold>(B)</bold> Percentage death and recovery in India. Panels <bold>(A)</bold> and <bold>(B)</bold> have been adopted from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/country/india/">https://www.worldometers.info/coronavirus/country/india/</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fgene-12-637362-g002.jpg"/></fig><p>States and cities of India harboring busy international airports (such as Kolkata in West Bengal; Ahmedabad, Surat in Gujrat; Mumbai in Maharashtra; New Delhi in Delhi and Chennai in Tamil Nadu) have shown high COVID-19 death rates. The total number of confirmed cases and death rates in Indian cities with important international airports has been tabulated in <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 3</xref>.</p><p>The incidences of COVID-19, death/total cases ratio and death rate have been higher in urban India than in rural areas. The death rate in urban India showed a decline in November, 2020 but, there is no significant change in the rural COVID-19 death rate (as evident from <xref ref-type="fig" rid="F3">Figure 3</xref>, <xref rid="T1" ref-type="table">Table 1</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 4</xref>). Early COVID-19 cases in India were primarily diagnosed in cities. Subsequent to the movement of migrant laborers from urban to rural areas and easing of transportation between rural and urban areas, there has been an increase in COVID-19 cases in rural India. High population density, greater economic activity, infrastructure development and movement of people contribute to constraints in social distancing in urban areas. Urban food habits (fast food, alcohol consumption), lifestyle patterns (improper sleep pattern, lack of physical exercise, stress) and high levels of pollution result in non-communicable lifestyle diseases (such as obesity, diabetes, and hypertension), which create additional complications in COVID-19 patients. Instances of such disorders are lower among rural population. Besides, rural lifestyle practices such as consumption of hot food, prolonged periods of sun exposure due to agricultural field work, lesser crowding, limited instances of handshaking may prove to be advantageous in conferring protection from COVID-19 (<xref rid="B99" ref-type="bibr">Mishra S. et al., 2020</xref>). Correlation analyses carried out in rural and semi rural areas indicate very weak positive correlation of COVID Fatality Rate (CFR) and hypertension; mild negative correlation of CFR with diabetes, implying that CFR is not necessarily related to co-morbidities such as hypertension and diabetes in rural areas<sup><xref ref-type="fn" rid="footnote9">9</xref></sup>. Although, reduced to some extent by the Swachh Bharat Mission, a large proportion of rural households avail open defecation and public toilet facilities. Also, many rural households travel long distances to carry drinking water from community source. Social distancing becomes a difficult proposition in such situations (<xref rid="B100" ref-type="bibr">Mishra S. V. et al., 2020</xref>). Further, many rural households do not have exclusive rooms for individuals, thus making self isolation difficult. So, careful monitoring of urban-rural movement and augmentation of rural healthcare facilities, wherever necessary, is required to control rise in rural COVID-19 cases and death rates.</p><fig id="F3" position="float" orientation="portrait"><label>FIGURE 3</label><caption><p>Schematic representation of the difference in death rate [expressed as (Death/total confirmed case) &#215; 100] in the urban and rural Indian population along with the probable factors contributing to the variation in death rate (%). The green downward arrow denotes decrease death rate (%) in urban India and the red upward arrow denotes slight increase death rate (%) in rural India.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fgene-12-637362-g003.jpg"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>TABLE 1</label><caption><p>Percentage death rate in urban and rural population across some states of India.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Sl.No</td><td valign="top" align="left" rowspan="1" colspan="1">States</td><td valign="top" align="left" rowspan="1" colspan="1">Urban or rural</td><td valign="top" align="left" rowspan="1" colspan="1">Districts considered for study</td><td valign="top" align="center" rowspan="1" colspan="1">Death rate (in %) (as on 10.06.2020)</td><td valign="top" align="center" rowspan="1" colspan="1">Death rate (in %) (as on 04.11.2020)</td><td valign="top" align="center" rowspan="1" colspan="1">Death rate (in %) (as on 30.12.2020)</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1.</td><td valign="top" align="left" rowspan="1" colspan="1">West Bengal</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Kolkata, North 24 Parganas, South 24 Parganas, Howrah, Hooghly</td><td valign="top" align="center" rowspan="1" colspan="1">4.45</td><td valign="top" align="center" rowspan="1" colspan="1">2.24</td><td valign="top" align="center" rowspan="1" colspan="1">2.15</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Malda, Paschim Medinipur, Purba Medinipur, Nadia, Puruliya</td><td valign="top" align="center" rowspan="1" colspan="1">0.91</td><td valign="top" align="center" rowspan="1" colspan="1">1.08</td><td valign="top" align="center" rowspan="1" colspan="1">1.15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2.</td><td valign="top" align="left" rowspan="1" colspan="1">Odisha</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Khordha, Nayagarh, Cuttack, Puri, Malkangiri</td><td valign="top" align="center" rowspan="1" colspan="1">0.44</td><td valign="top" align="center" rowspan="1" colspan="1">0.55</td><td valign="top" align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Ganjam, Balangir, Debagarh, Mayurbhanj, Jagatsinghapur</td><td valign="top" align="center" rowspan="1" colspan="1">0.12</td><td valign="top" align="center" rowspan="1" colspan="1">0.51</td><td valign="top" align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3.</td><td valign="top" align="left" rowspan="1" colspan="1">Bihar</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Patna, Gaya, Nalanda, Bhagalpur, Bengusarai</td><td valign="top" align="center" rowspan="1" colspan="1">0.56</td><td valign="top" align="center" rowspan="1" colspan="1">0.68</td><td valign="top" align="center" rowspan="1" colspan="1">0.70</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Samastipur, Banka, Madhubani, Kaimur, Madhepura</td><td valign="top" align="center" rowspan="1" colspan="1">0.31</td><td valign="top" align="center" rowspan="1" colspan="1">0.47</td><td valign="top" align="center" rowspan="1" colspan="1">0.50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4.</td><td valign="top" align="left" rowspan="1" colspan="1">Uttar Pradesh</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Lucknow, Ghaziabad, Agra, Meerut, Kanpur Nagar</td><td valign="top" align="center" rowspan="1" colspan="1">4.14</td><td valign="top" align="center" rowspan="1" colspan="1">1.75</td><td valign="top" align="center" rowspan="1" colspan="1">1.60</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Allahabad, Azamgarh, Jaunpur, Sitapur, Gorakhpur</td><td valign="top" align="center" rowspan="1" colspan="1">2.22</td><td valign="top" align="center" rowspan="1" colspan="1">1.50</td><td valign="top" align="center" rowspan="1" colspan="1">1.53</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5.</td><td valign="top" align="left" rowspan="1" colspan="1">Jharkhand</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Ranchi, Dhanbad, Bokaro, Purbi Singhbhum, Ramgarh</td><td valign="top" align="center" rowspan="1" colspan="1">1.95</td><td valign="top" align="center" rowspan="1" colspan="1">1.08</td><td valign="top" align="center" rowspan="1" colspan="1">1.12</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Giridih, Palamu, Hazaribagh, Pashchimi Singhbhum, Simdega</td><td valign="top" align="center" rowspan="1" colspan="1">0.38</td><td valign="top" align="center" rowspan="1" colspan="1">0.52</td><td valign="top" align="center" rowspan="1" colspan="1">0.57</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6.</td><td valign="top" align="left" rowspan="1" colspan="1">Madhya Pradesh</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Bhopal, Indore, Gwalior, Jabalpur, Ujjain</td><td valign="top" align="center" rowspan="1" colspan="1">4.21</td><td valign="top" align="center" rowspan="1" colspan="1">1.91</td><td valign="top" align="center" rowspan="1" colspan="1">1.61</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Dindori, Jhabua, Bhind, Morena, Rewa</td><td valign="top" align="center" rowspan="1" colspan="1">2.74</td><td valign="top" align="center" rowspan="1" colspan="1">0.75</td><td valign="top" align="center" rowspan="1" colspan="1">0.73</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7.</td><td valign="top" align="left" rowspan="1" colspan="1">Haryana</td><td valign="top" align="left" rowspan="1" colspan="1">Urban</td><td valign="top" align="left" rowspan="1" colspan="1">Gurgaon, Panipat, Faridabad, Rohtak, Sonipat</td><td valign="top" align="center" rowspan="1" colspan="1">2.12</td><td valign="top" align="center" rowspan="1" colspan="1">0.87</td><td valign="top" align="center" rowspan="1" colspan="1">0.92</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Rural</td><td valign="top" align="left" rowspan="1" colspan="1">Palwal, Rewari, Mewat, Jhajjar, Fatehabad</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1.19</td><td valign="top" align="center" rowspan="1" colspan="1">1.41</td></tr></tbody></table><table-wrap-foot><attrib><italic toggle="yes">Death rate = (Death/total confirmed case) &#215; 100; Death rate computed with data obtained on 10.06.2020, 04.11.2020 and 30.12.2020 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Bing.Com/Covid/Local/India">https://Bing.Com/Covid/Local/India</ext-link>.</italic></attrib></table-wrap-foot></table-wrap></sec><sec id="S2.SS2"><title>Association of COVID-19 With Other Co-morbidities in India</title><p>Globally, common co-morbidities such as hypertension, diabetes, asthma, cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), obesity, chronic kidney disease (CKD), cerebro-vascular accident (CVA), malignancy, and inflammatory conditions have been noted to worsen health status in COVID-19 positive patients (<xref rid="B126" ref-type="bibr">Renu et al., 2020</xref>). Medications used in these conditions often lead to upregulation of Angiotensin-converting enzyme 2 (ACE&#8722;2) receptor; thereby enhancing the possibility of ACE2 mediated viral entry and susceptibility to SARS-CoV-2 infection (<xref rid="B134" ref-type="bibr">Shahid et al., 2020</xref>). Communicable diseases such as tuberculosis and HIV-AIDS (Human immunodeficiency virus &#8211; Acquired Immuno Deficiency Syndrome) have also been associated with escalated severity and death rate in COVID-19 patients across the world. Sporadic studies from different Indian states/cities such as West Bengal and Jaipur revealed association of one or more co-morbid conditions with deaths in COVID-19 patients. Computational analysis based on Boolean search highlighted diabetes as the most prevalent co-morbidity in Indian COVID-19 patients, followed by hypertension (<xref rid="B141" ref-type="bibr">Singh and Misra, 2020</xref>). Co-morbidities in COVID-19 patients result in increased medical complications, incidence of hospitalization and high mortality rate. In order to deal with medical complications arising from COVID-19, it is vital to have knowledge regarding the SARS-CoV-2 strains and the viral mode of action within the host system.</p></sec><sec id="S2.SS3"><title>SARS-CoV-2 Strains Available in India and Their Evolution</title><p>Phylogenetic studies denote the causative agent of COVID-19 as belonging to the family <italic toggle="yes">Coronaviridae</italic>. Viruses belonging to this family have a single-stranded, (+) sense RNA genome of &#8764;30 kb (<xref rid="B167" ref-type="bibr">Yadav et al., 2020</xref>). During the 18th to 19th centuries, viruses from these families were known to cause infections only in animals (<xref rid="B31" ref-type="bibr">Cui et al., 2019</xref>). The first time it was discovered in humans was in mid 1965. This strain was referred as HCoV 229E in the United States. This was followed by an outbreak of coronavirus in France caused by another member of the same family, HCoV OC43 that led to 501 confirmed cases in 2000&#8211;2001. Till date seven different coronaviruses have been identified in this family that cause infection in humans. There have been five subsequent outbreaks in two decades prior to the recent pandemic caused by SARS-CoV-2 in December 2019 that originated from Wuhan city, China. Bioinformatics based analyses on SARS-CoV-2 genomes isolated from different countries shows its close relation with two bat origin SARS-CoV (bat-SL-CoVZC45 and bat-SL-CoVZXC21). Further, in-depth analysis of SARS-CoV-2 sequence exhibits 96.3% genome similarity with Bat CoV RaTG13 (<xref rid="B167" ref-type="bibr">Yadav et al., 2020</xref>). Upon comparison of SARS-CoV-2 with SARS-CoV, six different mutations were identified in ORF1a/b, S, ORF7b, and ORF8 genes. Moreover, similarity between RdRp and 3CLPro proteins has been reported. ORF8 and ORF10 show no homology with that of SARS-CoV strain (<xref rid="B70" ref-type="bibr">Kaur et al., 2020</xref>). Till now, no confirmed animal reservoir has been identified, although pangolins are claimed to be natural reservoirs due to the high similarity of the spike region between human SARS-CoV-2 and pangolin SARS-CoV (<xref rid="B8" ref-type="bibr">Andersen et al., 2020</xref>). Viruses belonging to this family have an anomalous feature of rapid mutation in their genome that causes variability in the strain. Studies are being conducted to understand the genetic diversity and evolution to establish a reference sequence for SARS-CoV-2 through mathematical modeling and Single Nucleotide Polymorphism (SNP) analysis of all the available sequences (<xref rid="B157" ref-type="bibr">Wang et al., 2020b</xref>). In the context of therapeutic drug and vaccine development, it is essential to monitor and track local and global genetic variations in the genome (<xref rid="B172" ref-type="bibr">Yin, 2020</xref>). A study of 3636 SARS-CoV-2 RNA sequences from 55 different countries revealed a remarkable mutation in the S protein at D614 amino acid position (D614G) among all the high-frequency mutations and was classified as A2a subtype. These high-frequency mutations in the SARS COV-2 genome have resulted in 11 different clusters of related sequences. Among these, O type is an ancestral type that arose from China. SARS-CoV-2 genotypes A, B, C have been described previously. These have been further divided into subtypes B, B1, B2, and B4 on the basis of mutations in the ORF8 region of SARS CoV-2. Genotype A possesses a mutation that is carried by all the B2 subtypes. A1a, a subtype of A, possesses a mutation similar to type C that may merge all these previously reported genetic variations in one cluster. There is inadequate information about the A2a subtype of SARS-CoV-2 that had spread widely in March. The A2a genotype of SARS CoV-2 consists of a non-synonymous mutation located near the S1-S2 junction similar to the A2 subtype. This non-synonymous mutation could possibly impact viral entry into the host cell (<xref rid="B13" ref-type="bibr">Biswas and Majumder, 2020</xref>). Thus, A2a variants could be important genetic variants for the development of effective vaccines and drugs against this virus. Further, sub-genotypes A3, A7, A1a, A2, and A6 have evolved from genotype A due to variation at the ORF1a, ORF3a, S, and nucleotide T514C respectively (<xref rid="B131" ref-type="bibr">Samaddar et al., 2020</xref>). Another group in India has examined 591 different novel coronaviruses and grouped them in five different clades. A total of 43% synonymous and 57% non-synonymous nucleotide substitutions were observed. The maximum number of non-synonymous substitutions was observed in the S protein (<xref rid="B129" ref-type="bibr">Saha et al., 2020</xref>). The presence of four SNPs at genomic positions 241, 3037, 144410, 23405 among 50&#8211;60% of the novel coronavirus population was deciphered by combining different bioinformatics (<xref rid="B150" ref-type="bibr">Tiwari and Mishra, 2020</xref>). However, epidemiological studies undertaken from time to time and surveillance of genetic variants among humans as well as in animals could be a major aid in the management of such outbreaks.</p></sec></sec><sec id="S3"><title>Viral Mode of Action: Immuno-Modulatory Action of Viral Proteins</title><p>Binding of SARS-CoV-2 spike (S) protein with host cell angiotensin-converting enzyme 2 (ACE2) aided by TMPRSS2 mediates viral entry. SARS-CoV-2 viral proteins (enlisted in <xref rid="T2" ref-type="table">Table 2</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 5</xref>) modulate host immune system and antagonize IFN response. COVID-19 pathophysiology is associated with aggressive pro-inflammatory responses (including IL-6, IL-1&#946;, IP-10, macrophage inflammatory protein 1&#945; (MIP1&#945;), MIP1&#946; and MCP1) and airway damage. Disease severity depends on viral load and the host immune response. Severe COVID-19 patients exhibit high level of pro-inflammatory macrophages, neutrophils and monocytes, which contribute to the cytokine storm with very high plasma levels of TNF, IL-12, IL-6, IL-10, IL-7, G-CSF, IP-10, MIP1&#945;, and MCP1 (<xref rid="B21" ref-type="bibr">Chen et al., 2020</xref>; <xref rid="B85" ref-type="bibr">Liao et al., 2020</xref>; <xref rid="B177" ref-type="bibr">Zhou et al., 2020</xref>). Vigorous pro-inflammatory response leads to airway epithelial and endothelial cell apoptosis, respiratory microvascular damage, vascular leakage and edema, thereby causing hypoxia and compromising blood gas exchange, resulting in acute respiratory distress syndrome (ARDS) (<xref rid="B171" ref-type="bibr">Ye et al., 2020</xref>; <xref rid="B174" ref-type="bibr">Zhang B. et al., 2020</xref>). Activation of complement pathways has been associated with microvascular injury and thrombosis in severe COVID infection (<xref rid="B90" ref-type="bibr">Magro et al., 2020</xref>).</p><table-wrap id="T2" position="float" orientation="portrait"><label>TABLE 2</label><caption><p>Comparative list of SARS-CoV and SARS-CoV-2 viral proteins involved in modulating the host anti-viral immune response.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Sl.No.</td><td valign="top" align="left" rowspan="1" colspan="1">Viral protein</td><td valign="top" align="left" rowspan="1" colspan="1">Category</td><td valign="top" align="justify" colspan="2" rowspan="1">Host immuno modulating function of viral proteins</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>SARS-CoV</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>SARS-CoV-2</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1.</td><td valign="top" align="left" rowspan="1" colspan="1">M protein</td><td valign="top" align="left" rowspan="1" colspan="1">Structural Protein (Important component of viral envelope)</td><td valign="top" align="left" rowspan="1" colspan="1">Increased M protein expression is linked with RIG-I, TBK1, IKK&#949;, and TRAF3 and hence, prevention of IRF3 and IRF7 activation. This results in significant decrease in induction of the interferon-&#946; promoter by dsRNA (<xref rid="B162" ref-type="bibr">Weiss and Leibowitz, 2011</xref>).</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2.</td><td valign="top" align="left" rowspan="1" colspan="1">N protein</td><td valign="top" align="left" rowspan="1" colspan="1">Structural Protein (Encodes for Nucleocapsid protein)</td><td valign="top" align="left" rowspan="1" colspan="1">Overexpression is associated with decreased IFN response via inhibition of IRF3 and NF-&#954;B responsive promoter mediated activation (<xref rid="B162" ref-type="bibr">Weiss and Leibowitz, 2011</xref>).</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3.</td><td valign="top" align="left" rowspan="1" colspan="1">Nsp1</td><td valign="top" align="left" rowspan="1" colspan="1">Non-Structural Protein</td><td valign="top" align="left" rowspan="1" colspan="1">Suppresses the activation of IRF3, c-Jun and NF-&#954;B, thereby blocking the interferon response and subsequent activation of interferon-dependent anti-viral proteins (such as ISG15 and ISG56) (<xref rid="B162" ref-type="bibr">Weiss and Leibowitz, 2011</xref>).</td><td valign="top" align="left" rowspan="1" colspan="1">Modulates and suppresses the host anti-viral immune response (<xref rid="B50" ref-type="bibr">Gordon et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4.</td><td valign="top" align="left" rowspan="1" colspan="1">Nsp3</td><td valign="top" align="left" rowspan="1" colspan="1">Non-Structural Protein</td><td valign="top" align="left" rowspan="1" colspan="1">Serves as papain like protease with de-ubiquitinating activity; could act as Type I Interferon antagonist (<xref rid="B162" ref-type="bibr">Weiss and Leibowitz, 2011</xref>).</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5.</td><td valign="top" align="left" rowspan="1" colspan="1">Nsp13</td><td valign="top" align="left" rowspan="1" colspan="1">Non-Structural Protein</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">Targets innate immune pathways such as Interferon (IFN) and NF-&#954;B pathways (<xref rid="B9" ref-type="bibr">Azkur et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6.</td><td valign="top" align="left" rowspan="1" colspan="1">Nsp15</td><td valign="top" align="left" rowspan="1" colspan="1">Non-Structural Protein</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">Targets the Interferon (IFN) pathway (<xref rid="B9" ref-type="bibr">Azkur et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7.</td><td valign="top" align="left" rowspan="1" colspan="1">ORF3a</td><td valign="top" align="left" rowspan="1" colspan="1">Accessory Protein</td><td valign="top" align="left" rowspan="1" colspan="1">Raises level of fibrinogen in lungs.</td><td valign="top" align="left" rowspan="1" colspan="1">Activates the NLRP3 inflammasome (<xref rid="B50" ref-type="bibr">Gordon et al., 2020</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Activates the NLRP3 inflammasome (<xref rid="B22" ref-type="bibr">Chen et al., 2019</xref>).</td><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Activates caspase-1.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Activates NF-&#954;B and JNK which in turn leads to upregulated expression of pro-inflammatory cytokines (such as IL8 and RANTES) (<xref rid="B107" ref-type="bibr">Narayanan et al., 2008</xref>).</td><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Mediates IL-1&#946; and IL-18 secretion (<xref rid="B22" ref-type="bibr">Chen et al., 2019</xref>; <xref rid="B50" ref-type="bibr">Gordon et al., 2020</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Induces increased apoptosis via caspase 8 and caspase 9-mediated pathways. Bax, p53 and p38 MAP kinase are also involved in ORF3a mediated apoptosis (<xref rid="B95" ref-type="bibr">McBride and Fielding, 2012</xref>; <xref rid="B22" ref-type="bibr">Chen et al., 2019</xref>).</td><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8.</td><td valign="top" align="left" rowspan="1" colspan="1">ORF3b</td><td valign="top" align="left" rowspan="1" colspan="1">Accessory Protein</td><td valign="top" align="left" rowspan="1" colspan="1">Enhances the production of cytokines and chemokines by regulating the transcriptional activity of RUNX1b. Inhibits Type I interferon (IFN) production and signaling (<xref rid="B107" ref-type="bibr">Narayanan et al., 2008</xref>; <xref rid="B95" ref-type="bibr">McBride and Fielding, 2012</xref>).</td><td valign="top" align="left" rowspan="1" colspan="1">IFN antagonist; regulates IRF3 activity (<xref rid="B50" ref-type="bibr">Gordon et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9.</td><td valign="top" align="left" rowspan="1" colspan="1">ORF6</td><td valign="top" align="left" rowspan="1" colspan="1">Accessory Protein</td><td valign="top" align="left" rowspan="1" colspan="1">Promotes DNA synthesis.</td><td valign="top" align="left" rowspan="1" colspan="1">Serves as a Type I Interferon (IFN) antagonist (<xref rid="B50" ref-type="bibr">Gordon et al., 2020</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Hampers Type I IFN production and signaling (<xref rid="B107" ref-type="bibr">Narayanan et al., 2008</xref>; <xref rid="B95" ref-type="bibr">McBride and Fielding, 2012</xref>).</td><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10.</td><td valign="top" align="left" rowspan="1" colspan="1">ORF7a</td><td valign="top" align="left" rowspan="1" colspan="1">Accessory Protein</td><td valign="top" align="left" rowspan="1" colspan="1">Triggers inflammatory response through activation of NF-&#954;B and IL8 promoter region (<xref rid="B107" ref-type="bibr">Narayanan et al., 2008</xref>).</td><td valign="top" align="left" rowspan="1" colspan="1">Mediates virus induced apoptosis (<xref rid="B50" ref-type="bibr">Gordon et al., 2020</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Promotes pro-inflammatory cytokines (such as IL8 and RANTES) production (<xref rid="B95" ref-type="bibr">McBride and Fielding, 2012</xref>).</td><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">11.</td><td valign="top" align="left" rowspan="1" colspan="1">ORF8b</td><td valign="top" align="left" rowspan="1" colspan="1">Accessory Protein</td><td valign="top" align="left" rowspan="1" colspan="1">Blocks the IFN-&#946; signaling pathway by ubiquitin-proteasome mediated degradation of IRF3 (<xref rid="B163" ref-type="bibr">Wong et al., 2018</xref>).</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.</td><td valign="top" align="left" rowspan="1" colspan="1">Orf9b</td><td valign="top" align="left" rowspan="1" colspan="1">Accessory Protein</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">Serves as a Type I Interferon (IFN) antagonist (<xref rid="B9" ref-type="bibr">Azkur et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13.</td><td valign="top" align="left" rowspan="1" colspan="1">Orf9c</td><td valign="top" align="left" rowspan="1" colspan="1">Accessory Protein</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="top" align="left" rowspan="1" colspan="1">Targets the NF-&#954;B pathway and hence the anti-viral innate immune response (<xref rid="B9" ref-type="bibr">Azkur et al., 2020</xref>).</td></tr></tbody></table></table-wrap></sec><sec id="S4"><title>Diagnostic Methods, Therapeutic Strategies and Government Initiatives to Combat COVID-19 in India</title><sec id="S4.SS1"><title>COVID-19 Diagnosis in India</title><p>Similarity in signs and symptoms with other respiratory infectious diseases (fever, chills, cough, and shortness of breath) put an extra burden on specialized COVID-19 diagnosis (<xref rid="B71" ref-type="bibr">Kaushik et al., 2020</xref>). Clinical manifestation of COVID 19 patients vary day to day and asymptomatic carriers of SARS-CoV-2 pose a challenge to our diagnostic approaches. ICMR and WHO have categorized COVID-19 as mild, moderate, and severe<sup><xref ref-type="fn" rid="footnote10">10</xref></sup> (<xref rid="B142" ref-type="bibr">Sivasankarapillai et al., 2020</xref>). Accurate and rapid diagnosis is needed to minimize substantial morbidity and mortality. Virus isolation, electron microscopy, genomic sequencing-the standard procedures for coronavirus diagnosis are time-consuming and costly. Thus, to examine a large number of patients, serological and laboratory-based methods such as CBC, AST, ALT, creatinine, LDH, ferritin examination, and molecular-based assays are being used on priority (<xref rid="B12" ref-type="bibr">Balachandar et al., 2020</xref>). India has set up several diagnostic and ilabs all over the country to test COVID-19 patients on the basis of qRT-PCR (<xref rid="B71" ref-type="bibr">Kaushik et al., 2020</xref>; <xref rid="B78" ref-type="bibr">Lamba, 2020</xref>). Diagnosis depends on several SARS-CoV-2 proteins, namely, spike (S), M, envelope (E), N, RdRp and ORF-1b-nsp14 (<xref rid="B6" ref-type="bibr">Alagarasu et al., 2020</xref>; <xref rid="B105" ref-type="bibr">Mourya et al., 2020</xref>). Initially, in India the first two SARS-COV-2 viruses were identified and confirmed by screening for viral genes (E, RdRp, and N protein of SARS-CoV-2) in 881 suspected cases by RT-PCR and next-generation sequencing (<xref rid="B167" ref-type="bibr">Yadav et al., 2020</xref>). The limited supply of positive controls has been overcome by the introduction of <italic toggle="yes">in vitro</italic> transcribed RNA from the National Institute of Virology (NIV) (<xref rid="B23" ref-type="bibr">Choudhary et al., 2020</xref>). SOPs for types of specimen collection and transportation were initially documented by ICMR-NIV (<xref rid="B51" ref-type="bibr">Gupta et al., 2020</xref>). To enhance the speed of detection, various rapid detection kits, CT scan and X-ray based techniques have been introduced from time to time. However, lack of accuracy of these techniques has prevented them from being used as standard procedures (<xref rid="B62" ref-type="bibr">Iyer et al., 2020</xref>). The production of IgG and IgM against COVID-19 takes 10&#8211;15 days from infection. This is a limitation for any antigen and antibody-based rapid detection kit (<xref rid="B57" ref-type="bibr">Hou et al., 2020</xref>). Recently, a CRISPR based fast and highly accurate diagnostic approach for COVID-19 has been introduced which employs nucleic acid readout of SARS-COV-2 (<xref rid="B87" ref-type="bibr">Lotfi and Rezaei, 2020</xref>). However, its implementation is highly challenging. CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), India has also developed an efficient and accurate detection tool named Feluda based on CRISPR-Cas9 technology, as an alternative to current gold standard RT-PCR technique. Feluda has received approval from the DCGI for commercial launch<sup><xref ref-type="fn" rid="footnote11">11</xref></sup>. In continuing efforts to discover a fast and rapid detection technique for SARS-CoV-2, an aptamer based assay has been developed at Translational Health Science and Technology Institute (THSTI). In this assay, nasal swab is used as the specimen for detection<sup><xref ref-type="fn" rid="footnote12">12</xref></sup>. Gargle lavage sample collected from COVID-19 patients was identified as an easy, alternative showing comparable efficiency as nasopharyngeal and oropharyngeal swab samples (<xref rid="B101" ref-type="bibr">Mittal et al., 2020</xref>). Monitoring of patients before and after recovery through epidemiological and immunological assays in the large cohort would help understanding the prognosis and pathogenesis of COVID-19 and shall also aid in preventing community transmission and post recovery complications.</p><sec id="S4.SS1.SSS1"><title>Detection Equipment</title><p>Standard diagnosis for infection requires real-time thermal cyclers which are used to perform RT-PCR, a robust and reliable detection technology (<xref rid="B29" ref-type="bibr">Corman et al., 2020</xref>). Technology centres under MSMEs began manufacturing components of Real Time Quantitative Micro PCR System in order to assemble the devices at a manufacturing unit in Visakhapatnam to ramp up the testing procedure<sup><xref ref-type="fn" rid="footnote13">13</xref></sup>. Apart from RT-PCR based testing, other approaches have also been demonstrated which involve two-step detection methods involving more affordable thermal cyclers (conventional PCR) and fluorescence spectrometers<sup><xref ref-type="fn" rid="footnote14">14</xref></sup>.</p></sec></sec><sec id="S4.SS2"><title>The Treatment of SARS-CoV-2 Infection and COVID-19: The Present Scenario</title><p>The SARS-CoV-2 infection and the COVID-19 pandemic have posed an unprecedented challenge to the medical fraternity. The treatment is restricted to the best supportive care and experimental medications. Targeting the viral entry, interaction of the virus with its host and the downstream signaling pathways using novel or repurposed drugs, is one of the strategies for the management of COVID-19. Several agents (enlisted in <xref rid="T3" ref-type="table">Table 3</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 6</xref>) have been tried based on their role in similar viral infections, or their prospective action on the novel corona virus.</p><table-wrap id="T3" position="float" orientation="portrait"><label>TABLE 3</label><caption><p>List of immuno-modulating drugs which are tried for COVID-19.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Sl.No.</td><td valign="top" align="left" rowspan="1" colspan="1">Name of drugs</td><td valign="top" align="left" rowspan="1" colspan="1">Type of anti viral or immune boosting action</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1.</td><td valign="top" align="left" rowspan="1" colspan="1">Chloroquine and Hydroxychloroquine (HCQS)</td><td valign="top" align="left" rowspan="1" colspan="1">May keep the virus out of host cells by blocking host receptor glycosylation or by breaking down viral protein production.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">May lead to suppression of pH-dependent steps of viral replication (<xref rid="B24" ref-type="bibr">Choudhary and Sharma, 2020</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">May exert immune-modulatory effects by inhibiting TNF-&#945; and IL6 production and may serve as a potent autophagy inhibitor.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Active against SARS-CoV-2 in vitro (<xref rid="B170" ref-type="bibr">Yao et al., 2020</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Leads to fast symptomatic improvement (fever, cough and chest imaging) (<xref rid="B30" ref-type="bibr">Cortegiani et al., 2020</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">HCQS and azithromycin combination leads to early viral clearance compared to HCQS alone (<xref rid="B47" ref-type="bibr">Gautret et al., 2020</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">US-FDA have cautioned against the use of HCQS for COVID-19 outside hospital settings <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Medicaldialogues.In/Medicine/News/Fda-Cautions-against-Use-of-Chloroquine-or-Hcqs-in-Covid-19-65165">https://Medicaldialogues.In/Medicine/News/Fda-Cautions-against-Use-of-Chloroquine-or-Hcqs-in-Covid-19-65165</ext-link> (accessed on May 5.2020)..</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2.</td><td valign="top" align="left" rowspan="1" colspan="1">Corticosteroids</td><td valign="top" align="left" rowspan="1" colspan="1">Exert immune-modulatory effects by inhibiting expression of genes encoding inflammatory molecules (<xref rid="B133" ref-type="bibr">Shaffer, 2020</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Dexamethasone proven to be a life saving drug for severe COVID-19.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3.</td><td valign="top" align="left" rowspan="1" colspan="1">Tocilizumab, Sarilumab and Situximab</td><td valign="top" align="left" rowspan="1" colspan="1">Monoclonal antibody (MAb) antagonists of the IL6 receptor.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Drugs commonly used for treatment of rheumatoid arthritis.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Severe forms of COVID-19 are associated with elevated levels of IL6, causing <underline>a</underline>cute <underline>r</underline>espiratory <underline>d</underline>istress <underline>s</underline>yndrome (ARDS) even upon reduction of viral load.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">These MAbs may play a vital role in reducing IL6 level and reduce instances of ARDS in COVID-19 patients (<xref rid="B19" ref-type="bibr">Chan et al., 2013</xref>; <xref rid="B88" ref-type="bibr">Luo et al., 2020</xref>; <xref rid="B97" ref-type="bibr">Michot et al., 2020</xref>; <xref rid="B133" ref-type="bibr">Shaffer, 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4.</td><td valign="top" align="left" rowspan="1" colspan="1">Fluvoxamine</td><td valign="top" align="left" rowspan="1" colspan="1">This serotonin re-uptake inhibitor may serve as an immune modulatory agent and shut down the inflammatory cascade from the endoplasmic reticulum by binding to the sigma-1 receptor (<xref rid="B133" ref-type="bibr">Shaffer, 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5.</td><td valign="top" align="left" rowspan="1" colspan="1">Remdesivir</td><td valign="top" align="left" rowspan="1" colspan="1">Antiviral pro drug.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">The active analog of the pro drug inhibits the viral RNA dependent RNA polymerase (RdRp) and preventing viral replication.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Remdesivir also evades the proofreading mechanism (exoribonuclease) of coronavirus (<xref rid="B43" ref-type="bibr">Ferner and Aronson, 2020</xref>; <xref rid="B159" ref-type="bibr">Wang M. et al., 2020</xref>) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Fda.Gov/Media/137564/Download">https://Www.Fda.Gov/Media/137564/Download</ext-link> (downloaded on May 5, 2020)..</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6.</td><td valign="top" align="left" rowspan="1" colspan="1">Azithromycin</td><td valign="top" align="left" rowspan="1" colspan="1">Broad spectrum macrolide antibiotic.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Used mainly for treatment of pulmonary, enteric and genitourinarytract infections. Acts as an acidotropic lipophilic weak base which modifies the pH of the endosome and trans-Golgi network and affects viral replication.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Interferes with viral entry by binding to viral spike (S) protein and humanreceptor protein ACE2 (angiotensin converting enzyme-2).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">May exert interferon mediated anti viral immune response (<xref rid="B24" ref-type="bibr">Choudhary and Sharma, 2020</xref>; <xref rid="B32" ref-type="bibr">Damle et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7.</td><td valign="top" align="left" rowspan="1" colspan="1">Baricitinib, Fedratinib, and Ruxolitinib</td><td valign="top" align="left" rowspan="1" colspan="1">Potent JAK inhibitors selectively inhibiting JAK-STAT signaling <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://Www.Chictr.Org.Cn/Showprojen.Aspx?Proj=49088">https://Www.Chictr.Org.Cn/Showprojen.Aspx?Proj=49088</ext-link> (<xref rid="B144" ref-type="bibr">Spinelli et al., 2020</xref>; <xref rid="B147" ref-type="bibr">Stebbing et al., 2020</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Exerts anti-inflammatory effects.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Might be effective in controlling the cytokine storm in COVID-19.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Baricitinib is also predicted to hamper ACE2 mediated endocytosis (<xref rid="B127" ref-type="bibr">Richardson et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8.</td><td valign="top" align="left" rowspan="1" colspan="1">Gimsilumab, Lenzilumab, Namilumab</td><td valign="top" align="left" rowspan="1" colspan="1">These are anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies. Blocks the inflammatory pathway in its early steps.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Being clinically tested for efficacy in COVID-19 (<xref rid="B148" ref-type="bibr">Tay et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9.</td><td valign="top" align="left" rowspan="1" colspan="1">Thalidomide</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic glutamic acid derivative.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Possess anti-inflammatory, anti-fibrotic, anti-angiogenesis, and immuno-modulatory effects.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inhibits and downregulates COX2, PGE2, TNF-&#945;, IL6 and IL1.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Used to treat severe H1N1 influenza-associated lung injury.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Being tested for its efficacy in treating cytokine storm and reducing lung injury and respiratory complications in COVID-19 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Clinicaltrials.Gov/Ct2/Show/Nct04273529">https://Clinicaltrials.Gov/Ct2/Show/Nct04273529</ext-link><sup>,</sup>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Clinicaltrials.Gov/Ct2/Show/Nct04273581">https://Clinicaltrials.Gov/Ct2/Show/Nct04273581</ext-link> (<xref rid="B72" ref-type="bibr">Khalil et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10.</td><td valign="top" align="left" rowspan="1" colspan="1">Nafamostat and Camostat</td><td valign="top" align="left" rowspan="1" colspan="1">Serine protease inhibitors which prevent SARS-CoV-2 entry by acting as antagonists to the serine protease TMPRSS2 (<xref rid="B168" ref-type="bibr">Yamamoto et al., 2016</xref>; <xref rid="B56" ref-type="bibr">Hoffmann et al., 2020</xref>; <xref rid="B175" ref-type="bibr">Zhang H. et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">11.</td><td valign="top" align="left" rowspan="1" colspan="1">Famotidine</td><td valign="top" align="left" rowspan="1" colspan="1">H2 receptor antagonist; may bind to SARS-CoV-2 encoded papain like protease and impair entry of SARS-CoV-2 (<xref rid="B133" ref-type="bibr">Shaffer, 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.</td><td valign="top" align="left" rowspan="1" colspan="1">Ivermectin</td><td valign="top" align="left" rowspan="1" colspan="1">Broad spectrum anti-parasitic macrolide drug.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Functions by binding and impairing the cell transport proteins that are vital for entry into the nucleus (<xref rid="B24" ref-type="bibr">Choudhary and Sharma, 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13.</td><td valign="top" align="left" rowspan="1" colspan="1">Favipiravir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits virus replication by binding and blocking the RdRp enzyme (<xref rid="B46" ref-type="bibr">Furuta et al., 2013</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Its incorporation in RNA also terminates viral protein synthesis (<xref rid="B64" ref-type="bibr">Jin et al., 2013</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Classically used against influenza virus.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Also acts on SARS-CoV-2 replication; used for mild and moderate COVID cases (<xref rid="B3" ref-type="bibr">Agrawal et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">14.</td><td valign="top" align="left" rowspan="1" colspan="1">Lopinavir/ Ritonavir</td><td valign="top" align="left" rowspan="1" colspan="1">Antiretroviral protease inhibitors, successfully used in HIV infection (<xref rid="B59" ref-type="bibr">Huang et al., 2015</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Combination of lopinavir/ritonavir used successfully for treatment of SARS with significantly fewer adverse clinical outcomes (<xref rid="B25" ref-type="bibr">Chu et al., 2004</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Lopinavir/ Ritonavir with Interferon 1b found promising in the marmoset model (<xref rid="B20" ref-type="bibr">Chan et al., 2015</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">15.</td><td valign="top" align="left" rowspan="1" colspan="1">APN01</td><td valign="top" align="left" rowspan="1" colspan="1">Soluble form of ACE2 delivered in high concentrations.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Could potentially block SARS-CoV-2 entry into target cells. Under clinical trial <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Pipelinereview.Com/Index.Php/2020022673884/Proteins-and-Peptides/Apeirons-Respiratory-Drug-Product-to-Start-Pilot-Clinical-Trial-to-Treat-Coronavirus-Disease-Covid-19-in-China.html">https://Pipelinereview.Com/Index.Php/2020022673884/Proteins-and-Peptides/Apeirons-Respiratory-Drug-Product-to-Start-Pilot-Clinical-Trial-to-Treat-Coronavirus-Disease-Covid-19-in-China.html</ext-link>.</td></tr></tbody></table></table-wrap><p>Indian Pharmaceuticals Cadila has tested the immunomodulator drug named Sepsivac (containing heat-killed <italic toggle="yes">Mycobacterium</italic> W (Mw)), on COVID-19 patients at PGIMER, Chandigarh in partnership with the Council of Scientific and Industrial Research (CSIR) to reduce the mortality of critically ill COVID-19 patients and have obtained promising results<sup><xref ref-type="fn" rid="footnote15">15</xref></sup>.</p><p>Apart from these drugs, the US FDA has approved use of convalescent plasma for severe life-threatening COVID infection as an investigational new drug (<xref rid="B38" ref-type="bibr">Duan et al., 2020</xref>). Its use has been documented in a series of cases (<xref rid="B58" ref-type="bibr">Huang et al., 2020</xref>; <xref rid="B173" ref-type="bibr">Zeng et al., 2020</xref>)<sup><xref ref-type="fn" rid="footnote16">16</xref></sup>. One small trial with five ventilated patients showed success. Its role is still not clear and US FDA is facilitating the use of hyperimmune globulin for COVID treatment (<xref rid="B96" ref-type="bibr">Mehta et al., 2020</xref>). US FDA recommended the use of convalescent plasma for emerging infections including COVID-19 on May 1, 2020 (see text footnote 2). The Indian Council of Medical Research (ICMR) began clinical trials with convalescent plasma in India to evaluate its safety and efficiency in controlling COVID-19 symptoms<sup><xref ref-type="fn" rid="footnote17">17</xref></sup><sup>,<xref ref-type="fn" rid="footnote18">18</xref></sup>. ICMR has recommended use of convalescent plasma for COVID-19 therapy. A plasma bank has been established in Delhi and Project PLATINA has been established in Maharashtra for treatment cum trial with plasma therapy<sup><xref ref-type="fn" rid="footnote19">19</xref></sup>.</p><p>Another approach for developing drugs targeting host immunity has been to express SARS-CoV-2 proteins in human cell lines and identify their human protein interacting partners. Of 332 interactions, 66 human proteins were found as druggable candidates that could be targeted by 29 FDA approved drugs, 12 compounds in clinical trials and 28 compounds in preclinical stage (<xref rid="B50" ref-type="bibr">Gordon et al., 2020</xref>). Further screening has helped in the identification of two pharmacological candidates that inhibit mRNA translation and are predicted to regulate Sigma1 and Sigma2 receptors. Besides, inhibitors targeting endocytosis have shown activity in vitro against other coronaviruses such as SARS CoV and MERS-CoV. These include chlorpromazine, ouabain and bufalin (<xref rid="B34" ref-type="bibr">de Wilde et al., 2014</xref>; <xref rid="B18" ref-type="bibr">Burkard et al., 2015</xref>). Their efficacy against SARS CoV-2 is yet to be tested. However, very high EC<sub>50</sub>/C<sub>max</sub> (half-maximal effective concentration value/peak serum concentration level) ratio at the typical dosages used is limiting their possible clinical use.</p><p>Natural killer cells play a role in the clearance of SARS-CoV. NK cell based products are in various stages of trial as anti-COVID-19 agents. The US-based Company Celularity has developed placenta derived NK cells CYNK-001 (<xref rid="B151" ref-type="bibr">Tu et al., 2020</xref>). Recombinant Interferon Type I exhibits broad spectrum activity against coronaviruses (<xref rid="B27" ref-type="bibr">Cinatl et al., 2003b</xref>; <xref rid="B136" ref-type="bibr">Sheahan et al., 2020</xref>). Clinical trials are currently in motion for the treatment of COVID-19 pneumonia (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04293887">NCT04293887</ext-link>). Trials are also ongoing to test the efficacy of mesenchymal stem cells from the umbilical cord and dental pulp to attenuate the inflammatory response of COVID-19 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04293692">NCT04293692</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04269525">NCT04269525</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04288102">NCT04288102</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04302519">NCT04302519</ext-link>). The World Health Organization&#8217;s (WHO) Solidarity trial including randomized and controlled clinical trials are set to test several protocols against COVID-19.</p></sec><sec id="S4.SS3"><title>COVID-19 Vaccine Developments &#8211; Present Indian Scenario</title><p>In the global fight against COVID-19, scientists from different countries are trying to decipher a potential therapeutic drug, vaccine, and early diagnostic tools. The SARS-CoV-2 &#8216;S&#8217; protein interacts with the ACE2 receptor and is a glycosylated protein, making this protein a good candidate for vaccine development (<xref rid="B115" ref-type="bibr">Othman et al., 2020</xref>). Globally several vaccine generation methods are being used against COVID-19, including a live attenuated vaccine, inactivated vaccine, replicating viral vector, non-replicating viral vector, DNA vaccine, peptide-based vaccine, recombinant protein, virus-like particle (VLP) and mRNA-based vaccine (<xref rid="B79" ref-type="bibr">Le et al., 2020</xref>). According to the WHO, there are currently 63 COVID-19 vaccines in clinical development and 172 vaccine candidates in pre clinical developmental stage as on 6th January, 2021 (see text footnote 3). Out of these 63 vaccines, about 20 vaccine candidates are in Phase III clinical trial (as enlisted in <xref rid="T4" ref-type="table">Table 4</xref>). Among these 20 vaccines, the efficacy report is available for five vaccines that include &#8220;BNT162 (Pfizer), mRNA 1273 (Moderna), chAdOX1nCOV19 (University of Oxford and AstraZeneca), BBIBP-CorV (Sinopharm) and Sputnik-V (Gamaleya Research Institute)<sup><xref ref-type="fn" rid="footnote20">20</xref></sup>. However, only three vaccines are available with the data published in peer reviewed journals till 5th January, 2021 namely, mRNA1273, BNT162, and chAdOX1nCOV19 (<xref rid="B10" ref-type="bibr">Baden et al., 2020</xref>; <xref rid="B121" ref-type="bibr">Polack et al., 2020</xref>; <xref rid="B155" ref-type="bibr">Voysey et al., 2020</xref>). Supporting data to answer such important question such as duration of herd immunity upon vaccination, requirement of booster doses for long term immunity and whether vaccine could help in the prevention of transmission is available for only chAdOX1nCOV19 vaccine till to date. Further, safety of the above mentioned vaccines needs to be evaluated in the populations that have not been included in the trials such as pregnant women (see text footnote 21).</p><table-wrap id="T4" position="float" orientation="portrait"><label>TABLE 4</label><caption><p>List of vaccines in Phase III trial across the world.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Sl.No.</td><td valign="top" align="left" rowspan="1" colspan="1">Name of vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Nature of vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Clinical Trial Phase</td><td valign="top" align="left" rowspan="1" colspan="1">Country of origin</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Ad5-nCoV</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant vaccine (adenovirus type 5 vector)</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">CanSino Biologics Inc/Beijing Institute of Biotechnology (China)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Covishield (Code name: AZD1222)</td><td valign="top" align="left" rowspan="1" colspan="1">Replication-deficient viral vector vaccine (adenovirus from chimpanzees)</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III (received approval for emergency use in United Kingdom and India)</td><td valign="top" align="left" rowspan="1" colspan="1">The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India (Multinational) (see text footnote 4) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Bbc.Com/News/Health-55280671">https://Www.Bbc.Com/News/Health-55280671</ext-link></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">CoronaVac</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated viral vaccine (formalin with alum adjuvant)</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Sinovac (China)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">COVAXIN</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated viral vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III (approved for emergency use in India)</td><td valign="top" align="left" rowspan="1" colspan="1">Bharat Biotech; National Institute of Virology (India) (see text footnote 7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">JNJ-78436735 (formerly Ad26.COV2-S)</td><td valign="top" align="left" rowspan="1" colspan="1">Non-replicating viral vector</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Johnson &amp; Johnson (Janssen Pharmaceutical) (United States)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA-1273</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA-based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III (received approval and presently in use in United States)</td><td valign="top" align="left" rowspan="1" colspan="1">Moderna; National Institute of Allergy and Infectious Diseases (NIAID) (United States) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Nature.Com/Articles/D41586-020-03593-7">https://Www.Nature.Com/Articles/D41586-020-03593-7</ext-link></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">New Crown COVID-19 Vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm, China) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Precisionvaccinations.Com/Vaccines/New-Crown-Covid-19-Vaccine">https://Www.Precisionvaccinations.Com/Vaccines/New-Crown-Covid-19-Vaccine</ext-link></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">NVX-CoV2373</td><td valign="top" align="left" rowspan="1" colspan="1">Protein based vaccine (Full length recombinant SARS CoV-2 spike protein nanoparticle vaccine adjuvanted with Matrix M)</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Novavax (Maryland); Serum Institute of India <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Ir.Novavax.Com/News-Releases/News-Release-Details/Novavax-Announces-Covid-19-Vaccine-Clinical-Development-Progress">https://Ir.Novavax.Com/News-Releases/News-Release-Details/Novavax-Announces-Covid-19-Vaccine-Clinical-Development-Progress</ext-link><sup>,</sup>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Verywellhealth.Com/Novavax-Covid-19-Vaccine-5093292">https://Www.Verywellhealth.Com/Novavax-Covid-19-Vaccine-5093292</ext-link></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">BNT162 (3 LNP-mRNAs)</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA-based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase II/III (Already in use in United Kingdom and United States)</td><td valign="top" align="left" rowspan="1" colspan="1">Pfizer; BioNTech; Fosun Pharma; Jiangsu Provincial Center for Disease Prevention and Control (Multinational) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Thehindu.Com/News/International/Uk-Approves-Pfizer-Biontech-Covid-19-Vaccine-for-Use/Article33228634.Ece">https://Www.Thehindu.Com/News/International/Uk-Approves-Pfizer-Biontech-Covid-19-Vaccine-for-Use/Article33228634.Ece</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nature.com/articles/d41586-020-03593-7">https://www.nature.com/articles/d41586-020-03593-7</ext-link>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">Sputnik-V Vaccine (rAd26-S+rAd5-S)</td><td valign="top" align="left" rowspan="1" colspan="1">Adeno viral vector based technology</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Gamaleya Research Institute; Health Ministry of the Russian Federation (Russia)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">BBIBP-CorV</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated viral vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Sinopharm + Beijing Institute of Biological Products (China) (<xref rid="B165" ref-type="bibr">Xia et al., 2021</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Recombinant SARS-CoV-2 vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology, Chinese Academy of Sciences (China)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">INO-4800</td><td valign="top" align="left" rowspan="1" colspan="1">DNA based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase II/III</td><td valign="top" align="left" rowspan="1" colspan="1">Inovio Pharmaceuticals and International Vaccine Institute (South Korea)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">CoVLP</td><td valign="top" align="left" rowspan="1" colspan="1">Coronavirus-Like Particle based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase II/III</td><td valign="top" align="left" rowspan="1" colspan="1">Medicago Inc. (Canada)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">CVnCoV</td><td valign="top" align="left" rowspan="1" colspan="1">RNA based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase II/III</td><td valign="top" align="left" rowspan="1" colspan="1">CureVac AG (Germany)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">UB-612</td><td valign="top" align="left" rowspan="1" colspan="1">Multitope peptide based S1-RBD-protein based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase II/III</td><td valign="top" align="left" rowspan="1" colspan="1">COVAXX; United Biomedical Inc</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">ZyCoV-D nCov vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">DNA based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Cadila Healthcare Ltd. Zydus Cadila, (India)<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Economictimes.Indiatimes.Com/Markets/Stocks/News/Cadila-Healthcare-Gains-3-as-Dcgi-Plays-Phase-Iii-Trials-of-Covid-Vaccine/Articleshow/80091363.Cms">https://Economictimes.Indiatimes.Com/Markets/Stocks/News/Cadila-Healthcare-Gains-3-as-Dcgi-Plays-Phase-Iii-Trials-of-Covid-Vaccine/Articleshow/80091363.Cms</ext-link></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">QazCovid-in</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated viral vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Research Institute for Biological Safety Problems (Rep of Kazakhstan)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 vaccine (vero cell)</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated viral vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Institute of Medical Biology; Chinese Academy of Medical Sciences (China)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">AG0301-COVID19</td><td valign="top" align="left" rowspan="1" colspan="1">DNA based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Phase II/III</td><td valign="top" align="left" rowspan="1" colspan="1">AnGes + Takara Bio + Osaka University (Japan)</td></tr></tbody></table><table-wrap-foot><attrib><italic toggle="yes">Vaccine Information obtained from World Health Organization (WHO) as on 06.01.2021 (see text footnote 3).</italic></attrib></table-wrap-foot></table-wrap><p>Apart from this, global mass immunization also encountered several challenges including financial, logistic and vaccine storage-related issues. The upper middle income countries started the vaccination in 2020. However, successful global vaccination or complete eradication of virus is possible only when low income and middle income countries get immunized in parallel. To overcome this situation, an International initiative termed COVAX facility has been set up to ensure equitable access to vaccine doses in Low income and middle income countries (LCMICs). COVAX aims at fixed vaccination for 20% of population belonging to the LCMICs by 2021. The vaccine will be provided by the AstraZeneca<sup><xref ref-type="fn" rid="footnote21">21</xref></sup>.</p><p>In India, COVAXIN, an indigenous inactivated COVID-19 vaccine, stable at 2&#8211;8&#176;C, manufactured by Bharat Biotech (Hyderabad, India) has currently entered the Phase III Human clinical trial and has recently been given emergency approval in India by the DCGI (see text footnote 7)<sup><xref ref-type="fn" rid="footnote22">22</xref></sup>. A plasmid DNA based vaccine, ZyCoV-D has been developed by Ahmedabad-based pharma company Cadila Healthcare (Zydus Cadila). It has been claimed that this vaccine is stable for 3 months at a temperature of 30&#176;C and longer at 2&#8211;8&#176;C. This thermostability could be beneficial for nationwide vaccination program due to minimalistic cold storage requirements. Phase III human clinical trials are being initiated for this vaccine. Besides these indigenous vaccines, several non indigenous vaccines of foreign origin are presently in various stages of clinical trial in India. Covishield, the vaccine developed by Oxford University and AstraZeneca has entered phase III trials in collaboration with the Serum Institute, Pune, India. Serum Institute has applied to DCGI for emergency regulatory authorization for Covishield use in India and has submitted additional requisite vaccine datasheet in this regard. This vaccine has been approved for emergency use in United Kingdom and has become the first COVID-19 vaccine candidate to have obtained emergency approval in India (see text footnote 4)<sup><xref ref-type="fn" rid="footnote23">23</xref></sup>. Covishield has the advantage of storage at 2&#8211;8&#176;C<sup><xref ref-type="fn" rid="footnote24">24</xref></sup>. Besides this, Dr. Reddy&#8217;s Laboratories Limited and Sputnik LLC (Russia) have been jointly conducting the clinical trial of Sputnik-V, the world&#8217;s first registered vaccine in India. This vaccine, ranking among world&#8217;s top 10 vaccine candidates is presently in Phase II Human Clinical Trial in India<sup><xref ref-type="fn" rid="footnote25">25</xref></sup>. The Biological E&#8217;s novel Covid-19 vaccine is also in the Phase I/II Human Clinical Trial in India (see text footnote 5). Ecological studies have highlighted lower number of infections and reduced COVID-19 mortality in countries, where BCG vaccination is made mandatory (<xref rid="B152" ref-type="bibr">Urashima et al., 2020</xref>). Randomized controlled trials of BCG-Danish have been conducted in Netherlands and Australia (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04327206">NCT04327206</ext-link></underline>, <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04328441">NCT04328441</ext-link></underline>). Serum Institute, Pune, India has conducted phase III trial of BCG vaccine VPM1002 to evaluate cross-protection to COVID-19<sup><xref ref-type="fn" rid="footnote26">26</xref></sup>. BCG vaccine could serve as a booster of innate immunity against COVID-19 via metabolic and epigenetic changes in a process called trained immunity (<xref rid="B109" ref-type="bibr">Netea et al., 2020</xref>).</p><p>Another important vaccine, BNT162 from Pfizer, which has already been rolled out in United Kingdom, United States and received emergency use approval in more than 10 countries, has extreme cold chain and storage requirement at &#8722;75&#176;C to keep its potency intact<sup><xref ref-type="fn" rid="footnote27">27</xref></sup>. Similarly, Moderna vaccine also has stringent storage requirement at &#8722;20&#176;C<sup><xref ref-type="fn" rid="footnote28">28</xref></sup>. Such stringent refrigeration needs may be difficult to achieve in developing countries and may render mass vaccination in India extremely challenging. Although India has cold storage facilities, they are limited and there are constraints especially in the case of handling large numbers of doses in a country as densely populated as India. Ramping up of cold chain and restructuring of cold storage facilities with synergistic aid from food storage and supply cold chain, may aid in overcoming vaccine storage issues to some extent<sup><xref ref-type="fn" rid="footnote29">29</xref></sup>. Another important factor involved in mass vaccination is the economic burden. The COVAX facility (led by WHO, CEPI, and GAVI) have emerged to financially support and enable equitable distribution of COVID-19 vaccines across the world<sup><xref ref-type="fn" rid="footnote30">30</xref></sup>. The Government of India (GOI) has also taken initiatives to bear the entire cost of vaccination and ensure mass immunization at nominal price<sup><xref ref-type="fn" rid="footnote31">31</xref></sup>. The Global Alliance for Vaccines and Immunizations (GAVI) has estimated an expenditure of $1.4 billion to $1.8 billion on part of India (the second most populous country after China) for the first phase vaccination, even after support from the COVAX facility<sup><xref ref-type="fn" rid="footnote32">32</xref></sup>. Moderna vaccine, apart from its cold requirement, is highly priced (at $10&#8211;450 per dose), which might be difficult to cater to the Indian population. However, aid from COVAX alliance and Government may help Moderna reduce its cost for India. Covishield and COVAXIN are reasonably priced with respect to the Indian scenario. Covishield have been priced at $3 per dose for government and approximately, $10 for private entities. Because of their local origin and normal refrigeration temperatures, these two vaccines will be easy for handling and supply chain distribution in India<sup><xref ref-type="fn" rid="footnote33">33</xref></sup><sup>,<xref ref-type="fn" rid="footnote34">34</xref></sup>.</p><p>COVID-19 mass vaccination drive in India shall soon be initiated with 30 crore people receiving the vaccines in the first phase. Healthcare workers, frontline workers and individuals aged above 50 will be vaccinated first according to the recommendations of the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC). In this regard, the COVID Vaccine Intelligence Network (Co-WIN) system has been developed as a digital platform for registration and real time monitoring of vaccination to pre registered individuals in India<sup><xref ref-type="fn" rid="footnote35">35</xref></sup>.</p></sec><sec id="S4.SS4"><title>Neutralizing Antibodies: Another Approach</title><p>Neutralization of the virus by antibodies is an important strategy for containing SARS-CoV-2. In SARS-CoV, the RBD122 (amino acids 318 to 510) of the S protein is primarily being targeted by neutralizing antibodies (<xref rid="B164" ref-type="bibr">Wong et al., 2004</xref>). The RBD of SARS-CoV and SARS CoV-2 are poorly conserved, so the majority of the monoclonal antibodies to SARS-CoV do not bind with or neutralize SARS CoV-2 (<xref rid="B156" ref-type="bibr">Wang et al., 2020a</xref>). Therapeutic monoclonal antibodies to SARS CoV-2 are being developed with the aid of phage library display, cloning of human B cell sequences from recovering patients and mouse immunization and hybridoma isolation. Ana&#239;ve semi synthetic library has been used to identify the anti-SARS-CoV-2 RBD human monoclonal antibody. This approach holds promise since the entire RBD remains conserved as of now (<xref rid="B118" ref-type="bibr">Parray et al., 2020</xref>). However, caution must be exercised, since animal studies of SARS CoV infection show that neutralizing antibodies to S protein may increase lung injury by aggravating inflammatory responses (<xref rid="B86" ref-type="bibr">Liu et al., 2019</xref>). Anti-S-IgG mediated proinflammatory responses occur due to binding of virus-anti-S-IgG complex with the Fc receptors (FcR) present on monocytes and macrophages (<xref rid="B86" ref-type="bibr">Liu et al., 2019</xref>). In addition, virus-anti-S-IgG complex may trigger the classical complement pathway leading to cellular damage.</p></sec><sec id="S4.SS5"><title>Indian Government Initiatives and Strategies to Combat COVID-19</title><sec id="S4.SS5.SSS1"><title>Personal Protective Equipment</title><p>Personal Protective Equipment (PPE) including face piece respirators, gloves, shoe covers and face shields are necessary for the protection of health workers from infection<sup><xref ref-type="fn" rid="footnote36">36</xref></sup>. N95 respirators, surgical masks or cloth masks are recommended to prevent respiratory transmission. Cloth masks may possibly be cost-effective in preventing community transmission in densely populated Asian countries (<xref rid="B145" ref-type="bibr">Sra et al., 2020</xref>). Unlike N95 respirators, simple cloth and surgical masks are non-disposable and can be potentially decontaminated routinely using alcohol/detergent washing, and moist heat treatment (<xref rid="B154" ref-type="bibr">Viscusi et al., 2009</xref>). To prevent contact transmission, disposable gloves are recommended for patient examination. Government of India is funding enterprises and enabling transfer of advanced technology for increased PPE production<sup><xref ref-type="fn" rid="footnote37">37</xref></sup>. However, supply of raw materials may be dependent on import and could be a bottle neck for large scale production in India (<xref rid="B40" ref-type="bibr">Feinmann, 2020</xref>).</p></sec><sec id="S4.SS5.SSS2"><title>Disinfection Instruments</title><p>COVID-19 may potentially remain transmissible on inanimate surfaces up to several days. Effective disinfection could be achieved using biocidal chemicals such as 70% ethanol, 0.1% aqueous sodium hypochlorite and 0.5% hydrogen peroxide solutions (<xref rid="B66" ref-type="bibr">Kampf, 2020</xref>; <xref rid="B67" ref-type="bibr">Kampf et al., 2020</xref>). 60&#8211;70% ethanol is recommended for sterilizing high-end biomedical equipment, while 0.1% aqueous sodium hypochlorite could be a viable solution for decontamination of large areas such as mass transit systems, hospital outdoors etc. Scientists from the Council of Scientific and Industrial Research (CSIR), India have claimed to develop a spraying procedure by using induction charged electrostatic spraying apparatus involving lower amounts of chemicals, charge based disinfection and large coverage in comparison with conventional high-volume sprayers<sup><xref ref-type="fn" rid="footnote38">38</xref></sup><sup>,<xref ref-type="fn" rid="footnote39">39</xref></sup> (<xref rid="B89" ref-type="bibr">Lyons et al., 2011</xref>). In line with other countries, drone-based disinfection methods have been proposed by Indian enterprises<sup><xref ref-type="fn" rid="footnote40">40</xref></sup>. Concern about the potential hazards of inhaling the aerosolized disinfectants still poses a challenge for large area disinfection (<xref rid="B75" ref-type="bibr">Kim et al., 2020</xref>).</p></sec><sec id="S4.SS5.SSS3"><title>Biomedical Equipment</title><p>Various medical equipment such as ventilators, sensor equipments including pulse-oximeter, infrared thermometer, multi parametric photo plethysmography (PPG) sensor, portable X-ray machine, fiberoptic bronchoscopes, video laryngoscopes, are required in monitoring and treatment of COVID-19 patients (<xref rid="B161" ref-type="bibr">Wax and Christian, 2020</xref>). The ventilator is a crucial equipment for critically ill patients with respiratory problems (<xref rid="B61" ref-type="bibr">Iyengar et al., 2020</xref>). Ventilators are costly (&#8764;$30,000) and there is a world-wide shortage of ventilators during the pandemic. India alone has a requirement for tens of thousands of ventilators<sup><xref ref-type="fn" rid="footnote41">41</xref></sup>. There is global endeavor to enhance production, lower cost and find alternatives. Engineers from Rail Coach Factory have claimed production of a low-cost prototype ventilator<sup><xref ref-type="fn" rid="footnote42">42</xref></sup>. Scientists at the CSIR laboratories are also developing 3D printed automatic ventilators and mechanical ventilators<sup><xref ref-type="fn" rid="footnote43">43</xref></sup> (<xref rid="B61" ref-type="bibr">Iyengar et al., 2020</xref>). An alternative for the ventilator, &#8220;Artificial Manual Breathing Unit (AMBU)&#8221; has been designed by researchers from the Postgraduate Institute of Medical Education and Research, Chandigarh (<xref rid="B61" ref-type="bibr">Iyengar et al., 2020</xref>). Recently, an Indian manufacturer has reported production of state-of-the-art ventilator costing less than $2000 (<xref rid="B2" ref-type="bibr">Agrawal, 2020</xref>).</p></sec><sec id="S4.SS5.SSS4"><title>Indigenous Medicinal Plants for Combating COVID-19</title><p>Antiviral herbal therapy has made enormous progress in the past decade (<xref rid="B35" ref-type="bibr">Dhama et al., 2018</xref>). Various medicinal plants and bioactive phyto-metabolites have been widely explored for effective control of several viral diseases such as influenza, hepatitis, human immunodeficiency virus (HIV), herpes simplex virus (HSV) and coxsackievirus infections (<xref rid="B5" ref-type="bibr">Akram et al., 2018</xref>). India harbors a diverse variety of medicinal plants and herbs with therapeutic potential (<xref rid="B102" ref-type="bibr">Mohanraj et al., 2018</xref>). The major indigenous medicinal plants with immuno-modulatory properties, which can potentially be explored for their role in boosting immunity and rendering protection from SARS-CoV-2 infection, have been summarized in <xref rid="T5" ref-type="table">Table 5</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Table 7</xref>.</p><table-wrap id="T5" position="float" orientation="portrait"><label>TABLE 5</label><caption><p>List of medicinal plants with major immune modulating properties.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Sl.No.</td><td valign="top" align="left" rowspan="1" colspan="1">NAME OF PLANTS</td><td valign="top" align="left" rowspan="1" colspan="1">Type of anti viral or immune targeting effects exerted</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1.</td><td valign="top" align="left" rowspan="1" colspan="1">Turmeric</td><td valign="top" align="left" rowspan="1" colspan="1">Curcumin in turmeric is an immune-modulatory agent.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Has an anti-viral, anti-microbial, anti-inflammatory and anti-oxidant activity.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Reduces pro-inflammatory cytokines like TNF-&#945;, IFN-&#947;, IL-1 and IL-8 via interaction with signal transducers such as NF-&#954;B, JAKs/STATSs, MAPKs and &#946;-catenin (<xref rid="B81" ref-type="bibr">Lelli et al., 2017</xref>; <xref rid="B65" ref-type="bibr">Kahkhaie et al., 2019</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2.</td><td valign="top" align="left" rowspan="1" colspan="1">Ashwagandha</td><td valign="top" align="left" rowspan="1" colspan="1">Activates immune response.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Triggers Th1 cytokines and interferon expression.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Increases expression of co-stimulatory molecules and integrins (<xref rid="B73" ref-type="bibr">Khan et al., 2009</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3.</td><td valign="top" align="left" rowspan="1" colspan="1">Cinnamon</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits allergen specific immune responses.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Protects from systemic inflammation and lung injury by attenuating NLRP3 inflammasome activation (<xref rid="B135" ref-type="bibr">Sharma et al., 2016</xref>; <xref rid="B166" ref-type="bibr">Xu et al., 2019</xref>; <xref rid="B114" ref-type="bibr">Ose et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4.</td><td valign="top" align="left" rowspan="1" colspan="1">Cardamom</td><td valign="top" align="left" rowspan="1" colspan="1">Has anti-microbial activity (<xref rid="B1" ref-type="bibr">Agnihotri and Wakode, 2010</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Exerts anti-inflammatory effect by inhibiting mediators such as COX2, TNF-&#945; and IL-6 (<xref rid="B91" ref-type="bibr">Majdalawieh and Carr, 2010</xref>; <xref rid="B69" ref-type="bibr">Kandikattu et al., 2017</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5.</td><td valign="top" align="left" rowspan="1" colspan="1">Holy Basil</td><td valign="top" align="left" rowspan="1" colspan="1">Exerts anti-inflammatory effects by modulating cellular and humoral immunity.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Elevates IFN-&#947; and IL-4.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Increases percentages of T-helper cells and NK-cells (<xref rid="B103" ref-type="bibr">Mondal et al., 2011</xref>; <xref rid="B68" ref-type="bibr">Kamyab and Eshraghian, 2013</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6.</td><td valign="top" align="left" rowspan="1" colspan="1">Cumin</td><td valign="top" align="left" rowspan="1" colspan="1">Thymoquinone in cumin has immuno-modulatory and anti-inflammatory properties. Suppresses inflammation by downregulation of COX2, IL-6, TNF-&#945; and NO production, and enhancement of IL-10 production.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Modulates cellular and humoral immunity and regulates Th1/Th2 immune response. Enhances NK cell mediated cytotoxicity (<xref rid="B92" ref-type="bibr">Majdalawieh and Fayyad, 2015</xref>; <xref rid="B48" ref-type="bibr">Gholamnezhad et al., 2016</xref>, <xref rid="B49" ref-type="bibr">2019</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7.</td><td valign="top" align="left" rowspan="1" colspan="1">Neem</td><td valign="top" align="left" rowspan="1" colspan="1">Has anti-inflammatory, antibacterial and antioxidant effects.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Attenuates release of pro-inflammatory cytokines such as TNF-&#945; and IL-6, thus modulating immune response; inhibits MCP-1 (monocyte chemoattractant protein-1) expression and recruitment of inflammatory cells (<xref rid="B53" ref-type="bibr">Hao et al., 2014</xref>; <xref rid="B80" ref-type="bibr">Lee et al., 2017</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8.</td><td valign="top" align="left" rowspan="1" colspan="1">Saffron</td><td valign="top" align="left" rowspan="1" colspan="1">Has anti-inflammatory, radical scavenging and immuno-modulatory properties (<xref rid="B14" ref-type="bibr">Bolhassani et al., 2014</xref>; <xref rid="B104" ref-type="bibr">Moshiri et al., 2015</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">9.</td><td valign="top" align="left" rowspan="1" colspan="1">Amlaki</td><td valign="top" align="left" rowspan="1" colspan="1">Has anti-inflammatory and immune-regulating activities.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Promotes NK cell function and Antibody-dependent cellular cytotoxicity (ADCC) (<xref rid="B169" ref-type="bibr">Yang and Liu, 2014</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">10.</td><td valign="top" align="left" rowspan="1" colspan="1">Brahmi</td><td valign="top" align="left" rowspan="1" colspan="1">Has immunomodulatory effectsHttp://Nopr.Niscair.Res.In/Handle/123456789/41986.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Mediates anti inflammatory effects by preventing the release of pro-inflammatory cytokines such as IL6 and TNF-&#945; from microglial cells and the immune cells of the brain (<xref rid="B108" ref-type="bibr">Nemetchek et al., 2017</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">11.</td><td valign="top" align="left" rowspan="1" colspan="1">Moringa</td><td valign="top" align="left" rowspan="1" colspan="1">Activates CD8<sup>+</sup> T cells, promotes IL-10, IL-2, IL-6 and TNF-&#945; production (<xref rid="B28" ref-type="bibr">Coriolano et al., 2018</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12.</td><td valign="top" align="left" rowspan="1" colspan="1">Liquorice Root (Yashtimadhu)</td><td valign="top" align="left" rowspan="1" colspan="1">Glycyrrhizin, the active compound of the liquorice root, inhibits SARS-associated coronavirus replication (<xref rid="B26" ref-type="bibr">Cinatl et al., 2003a</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Reduces virus uptake by host cells (especially in case of influenza virus) (<xref rid="B106" ref-type="bibr">Mousa, 2017</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Glycyrrhizin also stimulates IFN-&#947; production by T cells.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Exerts anti-inflammatory effects by inhibiting iNOS, COX2, IL-1&#946;, TNF-&#945;, IL-5 and IL-6 or by blocking trans-activation of NF-&#954;B (<xref rid="B77" ref-type="bibr">Kuang et al., 2018</xref>; <xref rid="B45" ref-type="bibr">Fouladi et al., 2019</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13.</td><td valign="top" align="left" rowspan="1" colspan="1">Shatavari</td><td valign="top" align="left" rowspan="1" colspan="1">Modulates the Th1/Th2 balance; promotes IgG secretion and IL-12 production; and inhibits IL-6 production (<xref rid="B120" ref-type="bibr">Pise et al., 2015</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">14.</td><td valign="top" align="left" rowspan="1" colspan="1">Coriander</td><td valign="top" align="left" rowspan="1" colspan="1">Has anti-inflammatory activity and boosts immunity (<xref rid="B84" ref-type="bibr">Li et al., 2016</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">15.</td><td valign="top" align="left" rowspan="1" colspan="1">Kapikacchu (Velvet Beans)</td><td valign="top" align="left" rowspan="1" colspan="1">Modulates immune mediators such as NF-&#954;B, IL-6, IFN-&#955;, TNF-&#945;, IL-1&#946;, iNOS and IL-2 in the central nervous system (<xref rid="B123" ref-type="bibr">Rai et al., 2017</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Boosts the innate immune response (<xref rid="B130" ref-type="bibr">Saiyad Musthafa et al., 2018</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">16.</td><td valign="top" align="left" rowspan="1" colspan="1">Ajwain</td><td valign="top" align="left" rowspan="1" colspan="1">Acts as an anti-inflammatory agent and exerts bronchodilatory effect (<xref rid="B16" ref-type="bibr">Boskabady et al., 2005</xref>, <xref rid="B15" ref-type="bibr">2007</xref>; <xref rid="B11" ref-type="bibr">Bairwa et al., 2012</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">17.</td><td valign="top" align="left" rowspan="1" colspan="1">Manjishtha</td><td valign="top" align="left" rowspan="1" colspan="1">Serves as potential anti-inflammatory agent and immune modulator.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Increases functions of the lymphatic system <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="Http://Www.Ijtsrd.Com/Papers/Ijtsrd9616.Pdf">Http://Www.Ijtsrd.Com/Papers/Ijtsrd9616.Pdf</ext-link> (<xref rid="B137" ref-type="bibr">Shen et al., 2018</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">18.</td><td valign="top" align="left" rowspan="1" colspan="1">Bibhitaki</td><td valign="top" align="left" rowspan="1" colspan="1">Boosts immunity <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Netmeds.Com/Health-Library/Post/Bibhitaki-5-Ways-This-Traditional-Fruit-Boosts-Your-Immunity">https://Www.Netmeds.Com/Health-Library/Post/Bibhitaki-5-Ways-This-Traditional-Fruit-Boosts-Your-Immunity</ext-link>.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">19.</td><td valign="top" align="left" rowspan="1" colspan="1">Guduchi, Giloy (Tinospora)</td><td valign="top" align="left" rowspan="1" colspan="1">Serves as anti-oxidant and anti-inflammatory agent.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Regulates NF- &#234;B signaling and production of pro-inflammatory mediators (<xref rid="B36" ref-type="bibr">Dhama et al., 2017</xref>; <xref rid="B54" ref-type="bibr">Haque et al., 2017</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">20.</td><td valign="top" align="left" rowspan="1" colspan="1">Haritaki</td><td valign="top" align="left" rowspan="1" colspan="1">Possesses anti-inflammatory and wound healing properties (<xref rid="B125" ref-type="bibr">Ratha and Joshi, 2013</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">21.</td><td valign="top" align="left" rowspan="1" colspan="1">Cinchona Bark</td><td valign="top" align="left" rowspan="1" colspan="1">Source of chloroquine, a common anti-malarial drug; exerts an effect on SAR CoV-2 by immune modulation and blockage of viral entry (<xref rid="B82" ref-type="bibr">Lentini et al., 2020</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">22.</td><td valign="top" align="left" rowspan="1" colspan="1">Shatapushpa (Fennel)</td><td valign="top" align="left" rowspan="1" colspan="1">Suppresses the immune response (<xref rid="B33" ref-type="bibr">Darzi et al., 2018</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Regulates Th17 and Treg immune response (<xref rid="B176" ref-type="bibr">Zhang et al., 2018</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">23.</td><td valign="top" align="left" rowspan="1" colspan="1">Triphala</td><td valign="top" align="left" rowspan="1" colspan="1">Exerts an anti-inflammatory effect via decreased expression of inflammatory mediators such as IL-17, COX-2, iNOS, TNF-&#945;, IL-1&#946;, VEGF, IL-6 and RANKL by preventing NF-&#954;B activation (<xref rid="B119" ref-type="bibr">Peterson et al., 2017</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">24.</td><td valign="top" align="left" rowspan="1" colspan="1">Jatiphala (Nutmeg)</td><td valign="top" align="left" rowspan="1" colspan="1">Has immuno-modulatory functions.</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Macelignan in nutmeg has anti-inflammatory property and inhibits Th2 cytokines such as IL-4 (<xref rid="B139" ref-type="bibr">Shin et al., 2013</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">25.</td><td valign="top" align="left" rowspan="1" colspan="1">Jatamansi</td><td valign="top" align="left" rowspan="1" colspan="1">Has anti-inflammatory, immuno-modulatory and wound-healing properties (<xref rid="B117" ref-type="bibr">Pandey et al., 2013</xref>; <xref rid="B52" ref-type="bibr">Han et al., 2017</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">26.</td><td valign="top" align="left" rowspan="1" colspan="1">Vidanga</td><td valign="top" align="left" rowspan="1" colspan="1">Ameliorates pro-inflammatory cytokines and suppresses TNF-&#945; production (<xref rid="B140" ref-type="bibr">Shirole et al., 2015</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">27.</td><td valign="top" align="left" rowspan="1" colspan="1">Gokshura (Tribulus)</td><td valign="top" align="left" rowspan="1" colspan="1">Can reduce inflammation and fibrosis in the lungs by lowering the expression of IL-6, IL-8, TNF-&#945; and TGF&#946;1 (<xref rid="B122" ref-type="bibr">Qiu et al., 2019</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">28.</td><td valign="top" align="left" rowspan="1" colspan="1">Bhringaraj (Eclipta)</td><td valign="top" align="left" rowspan="1" colspan="1">Exerts anti-inflammatory effects by regulating the NF-&#954;B pathway and the production of pro-inflammatory mediators (<xref rid="B41" ref-type="bibr">Feng et al., 2019</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">29.</td><td valign="top" align="left" rowspan="1" colspan="1">Punarnava (Boerhavia)</td><td valign="top" align="left" rowspan="1" colspan="1">Has anti-inflammatory properties (<xref rid="B98" ref-type="bibr">Mishra et al., 2014</xref>).</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Punarnavine, an alkaloid in Boerhavia exerts immuno-modulatory activities by reducing TNF-&#945;, IL-1&#946;, IL-6 production, and by increasing the titer of circulating antibody (<xref rid="B94" ref-type="bibr">Manu and Kuttan, 2009</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">30.</td><td valign="top" align="left" rowspan="1" colspan="1">Bhunimba (Andrographis)</td><td valign="top" align="left" rowspan="1" colspan="1">Has anti-inflammatory and immuno-modulatory effects (<xref rid="B60" ref-type="bibr">Islam et al., 2018</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">31.</td><td valign="top" align="left" rowspan="1" colspan="1">Shankha pushpi (Dwarf morning glory)</td><td valign="top" align="left" rowspan="1" colspan="1">Possesses anti-bacterial and immuno-modulating activity (<xref rid="B110" ref-type="bibr">Nguyen et al., 2016</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">32.</td><td valign="top" align="left" rowspan="1" colspan="1">Vidari (Indian Kudzu)</td><td valign="top" align="left" rowspan="1" colspan="1">Serves as an immune booster and an anti-inflammatory agent by inhibiting inflammatory mediators such as CRP, NF-&#954;B, COX-2, iNOS, TNF-&#945;, IL-1&#946; and IL-6 (<xref rid="B93" ref-type="bibr">Maji et al., 2014</xref>).</td></tr></tbody></table></table-wrap><p>The Ministry of Ayush under the Govt. of India has recommended use of indigenous herbal plants and spices namely, tulsi, cinnamon, dry ginger, black pepper, turmeric, coriander, cumin and garlic for enhancing immunity<sup><xref ref-type="fn" rid="footnote44">44</xref></sup>. Besides, the Ministry of Ayush has formulated a collection of four ayurvedic herbs namely, ashwagandha, guduchi, yasthimadhu, peepli; and a drug named Ayush 64 for combating COVID-19. The Ministry of Ayush along with the CSIR have initiated the process of validating the efficacy of these formulations against COVID-19 in the month of May, 2020 and the outcomes of these trials are expected to be available soon<sup><xref ref-type="fn" rid="footnote45">45</xref></sup><sup>,<xref ref-type="fn" rid="footnote46">46</xref></sup><sup>,<xref ref-type="fn" rid="footnote47">47</xref></sup>.</p></sec><sec id="S4.SS5.SSS5"><title>Artificial Intelligence in Combating COVID-19</title><p>The worldwide outbreak of SARS-CoV-2 has resulted in a tremendous dearth of clinical equipment. In order to contain the pandemic effectively, large scale testing and diagnosis are required. This is evident from the successful containment of SARS-CoV-2 virus in countries that have been able to perform mass testing of possibly infected people and contact tracing. RT-PCR serves as the gold standard test for validating SARS-CoV-2 infection. Inadequate testing capability in most countries, along with the high dependency of the RT-PCR test on the swab technique, has spurred the need to search for alternative methods that allow COVID-19 diagnosis.</p><sec id="S4.SS5.SSS5.Px1"><title>CT scan in COVID-19</title><p>The chest X-ray and thoracic computed tomography (CT) are examples of easily accessible medical imaging equipment, which assists clinicians in diagnosis. CT images may serve as a visual indicator of coronavirus infection for radiologists (<xref rid="B39" ref-type="bibr">Duncan and Ayache, 2000</xref>). While RT-PCR may take up to 24 h and needs multiple tests for conclusive results, chest CT combined with certain health symptoms can be used as an effective diagnostic tool in clinical practice for rapid screening of COVID-19 patients. There is a high chance that COVID-19 patients can be diagnosed accurately by using chest radiography images (<xref rid="B153" ref-type="bibr">van Ginneken et al., 2001</xref>; <xref rid="B143" ref-type="bibr">Sluimer et al., 2006</xref>). However, manual examination of CT scans for COVID-19 diagnosis is a labor-intensive and time-taking process. Besides, clinical presentation of COVID-19 in CT images is similar to other forms of viral pneumonia, which makes diagnosis even more difficult. A dependable computer-aided diagnostic system for COVID-19 may have huge implication in clinical practice for improving the detection efficiency while alleviating the radiologist&#8217;s workload (<xref rid="B37" ref-type="bibr">Dong et al., 2020</xref>; <xref rid="B138" ref-type="bibr">Shi et al., 2020</xref>). COVID-19 lesions in CT scans have a wide range of presentation in terms of appearance, size, and location in lungs, so, developing a system using either classical image processing approaches or conventional machine learning techniques relying on handcrafted features, is a challenging task. Recently, artificial intelligence (AI) has shown promise. It warrants better safety, higher accuracy and efficacy in imaging compared to the traditional, laborious imaging workflows. Alongside pioneering the basic clinical research, AI have enormous application in recent COVID-19 scenario which include provision for well allocated imaging platform, segmentation of infected and unaffected regions of lungs, clinical evaluation and diagnosis (<xref rid="B158" ref-type="bibr">Wang J. et al., 2020</xref>; <xref rid="B160" ref-type="bibr">Wang X. et al., 2020</xref>).</p></sec><sec id="S4.SS5.SSS5.Px2"><title>Role of deep learning</title><p>Deep learning technology which lies central to current concept of Artificial Intelligence has been effective in automated detection of lung diseases with high diagnostic accuracy. However, there are challenges when developing AI-empowered deep learning technologies for COVID-19 screening (<xref rid="B111" ref-type="bibr">Oh et al., 2020</xref>; <xref rid="B128" ref-type="bibr">Roy et al., 2020</xref>). Most of the deep learning based methods require annotating the lesions in CT volumes for effective disease detection. Annotating lesions and labeling of annotations are laborious and time consuming, and hence, are not desirable in times of rapid COVID-19 outbreak and simultaneous shortage of radiologists. Therefore, the major challenge of AI-empowered solutions is to determine the potential of a deep learning model based on patients&#8217; chest CT volumes for automated and accurate COVID-19 diagnosis. It should require nominal expert annotation and should be easily trained, which will be extremely advantageous in developing AI solution rapidly for COVID-19 diagnosis. Due to the constraints of hardware resources, a major challenge is to educate a deep learning model using volumetric CT scans. Another problem is the inter-class similarity and variation across pneumonia lesions. Finally, the lung CT scan images from patients with pneumonia harbor large portions of non-lesion regions, which exhibit wide range of complex tissue level variations. These non-lesion regions often exert a negative impact on the overall performance of AI-based solutions.</p></sec></sec><sec id="S4.SS5.SSS6"><title>Mobile Applications and Social Distancing Strategies</title><p>Aarogya Setu has been developed as a digital mobile COVID-19 tracking application, by the National Informatics Centre under the initiative of the Ministry of Electronics and Information Technology, Govt. of India, for effective awareness, management and mitigation of COVID-19 (<xref rid="B76" ref-type="bibr">Kodali et al., 2020</xref>)<sup><xref ref-type="fn" rid="footnote48">48</xref></sup><sup>,<xref ref-type="fn" rid="footnote49">49</xref></sup>. The Delhi Government has also launched the Delhi Corona app to create public awareness regarding availability of hospital facilities for COVID-19 treatment and also for complaint redressal regarding refusal to admit COVID-19 patients by hospitals with available facilities<sup><xref ref-type="fn" rid="footnote50">50</xref></sup><sup>,<xref ref-type="fn" rid="footnote51">51</xref></sup><sup>,<xref ref-type="fn" rid="footnote52">52</xref></sup>. Apart from these mobile applications, the Govt. of India has promoted strict social distancing to contain spread of COVID-19 amongst the Indian population (<xref rid="B116" ref-type="bibr">Paital et al., 2020</xref>).</p></sec></sec></sec><sec id="S5"><title>Discussion</title><p>The COVID-19 health crisis has created a stir in the whole world including in India. There has been a global endeavor in terms of disease diagnosis, drug repurposing and vaccine development to combat this pandemic. In addition to actively participating in these efforts to improve therapeutics and vaccine development against SARS-CoV-2; the Government of India has taken several initiatives and measures to further contain the disease. The total numbers of active cases in India reached a peak in the month of September, 2020 and have reduced subsequently. Although there have been 148,774 deaths in India till December 30, 2020; the recovery rate of COVID-19 patients in India has increased to about 98.51% as on December 30, 2020 (see text footnote 8). COVID-19 infection may exert detrimental long term effects on organs such as lungs, liver, kidney, brain. and heart (<xref rid="B55" ref-type="bibr">Heneka et al., 2020</xref>). These may even last after recovery from COVID-19 and lead to life-threatening health issues<sup><xref ref-type="fn" rid="footnote53">53</xref></sup>. Several clinical parameters such as blood levels of inflammatory mediators, neutrophil to lymphocyte ratio (NLR) and CT scan severity score have been evaluated for highlighting disease progression and the risk for development of post recovery complications such as pulmonary fibrosis, ARDS, neurological disorder or even multi-organ failure (<xref rid="B42" ref-type="bibr">Feng et al., 2020</xref>). Identification of blood borne easily detectable biomarkers could potentially stratify COVID-19 based on its severity and enable early prediction of progression to post recovery complications, thereby leading to better post COVID care and effective control of deaths due to such complications.</p></sec><sec id="S6"><title>Author Contributions</title><p>All the authors reviewed the literature, wrote the review, edited, and approved the manuscript.</p></sec><sec sec-type="COI-statement" id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> Research support and publication charges are funded by Bose Institute Intramural Fund.</p></fn></fn-group><ack><p>SM was grateful to the Department of Science and Technology, Govt. of India for the DST-Inspire Fellowship. MK was supported by the Council for Scientific and Industrial Research Emeritus Scientist Scheme (21(1088)/19/EMR-II). JB was supported by the J.C. Bose National Fellowship (SB/S2/JCB-049/2016).</p></ack><fn-group><fn id="footnote1"><label>1</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Covid19.Who.Int/">Covid19.Who.Int/</ext-link></p></fn><fn id="footnote2"><label>2</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/Vaccines-Blood-Biologics/Investigational-New-Drug-Ind-or-Device-Exemption-Ide-Process-Cber/Recommendations-Investigational-Covid-19-Convalescent-Plasma">https://www.fda.gov/Vaccines-Blood-Biologics/Investigational-New-Drug-Ind-or-Device-Exemption-Ide-Process-Cber/Recommendations-Investigational-Covid-19-Convalescent-Plasma</ext-link></p></fn><fn id="footnote3"><label>3</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/Publications/M/Item/Draft-Landscape-of-Covid-19-Candidate-Vaccines">https://www.who.int/Publications/M/Item/Draft-Landscape-of-Covid-19-Candidate-Vaccines</ext-link></p></fn><fn id="footnote4"><label>4</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Timesofindia.Indiatimes.Com/India/Oxford-Covid-Vaccine-Set-to-Become-First-to-Get-Approval-in-India-Report/Articleshow/80059745.Cms">https://Timesofindia.Indiatimes.Com/India/Oxford-Covid-Vaccine-Set-to-Become-First-to-Get-Approval-in-India-Report/Articleshow/80059745.Cms</ext-link></p></fn><fn id="footnote5"><label>5</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Vaccine.Icmr.Org.In/Covid-19-Vaccine">https://Vaccine.Icmr.Org.In/Covid-19-Vaccine</ext-link></p></fn><fn id="footnote6"><label>6</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.bharatbiotech.com/covaxin.html">https://www.bharatbiotech.com/covaxin.html</ext-link></p></fn><fn id="footnote7"><label>7</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.expresspharma.in/covid19-updates/dcgi-approves-covishield-and-covaxin-for-restricted-emergency-use-in-india/">https://www.expresspharma.in/covid19-updates/dcgi-approves-covishield-and-covaxin-for-restricted-emergency-use-in-india/</ext-link></p></fn><fn id="footnote8"><label>8</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Worldometers.Info/Coronavirus/Country/India/">https://Www.Worldometers.Info/Coronavirus/Country/India/</ext-link></p></fn><fn id="footnote9"><label>9</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Thehindu.Com/Data/Data-Lower-Covid-19-Fatality-Rate-in-Rural-Areas-Not-Necessarily-Due-to-Lower-Share-of-Co-Morbidities-among-Rural-Population/Article32620632.Ece">https://Www.Thehindu.Com/Data/Data-Lower-Covid-19-Fatality-Rate-in-Rural-Areas-Not-Necessarily-Due-to-Lower-Share-of-Co-Morbidities-among-Rural-Population/Article32620632.Ece</ext-link></p></fn><fn id="footnote10"><label>10</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.expresshealthcare.in/covid19-updates/icmr-revises-treatment-protocol-for-covid-19-patients/421792/">https://www.expresshealthcare.in/covid19-updates/icmr-revises-treatment-protocol-for-covid-19-patients/421792/</ext-link></p></fn><fn id="footnote11"><label>11</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Science.Thewire.In/the-Sciences/Explained-Feluda-Covid-19-Test-India-Crispr-Technology/">https://Science.Thewire.In/the-Sciences/Explained-Feluda-Covid-19-Test-India-Crispr-Technology/</ext-link></p></fn><fn id="footnote12"><label>12</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Journosdiary.Com/2020/07/12/Aptamer-Based-Assay-Developed-for-Coronavirus-Detection/">https://Journosdiary.Com/2020/07/12/Aptamer-Based-Assay-Developed-for-Coronavirus-Detection/</ext-link></p></fn><fn id="footnote13"><label>13</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Pib.Gov.In/Pressreleasepage.Aspx?Prid=1623027">https://Pib.Gov.In/Pressreleasepage.Aspx?Prid=1623027</ext-link></p></fn><fn id="footnote14"><label>14</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Hindustantimes.Com/India-News/Iisc-Comes-up-with-an-Affordable-Two-Step-Method-to-Scale-up-Rt-Pcr-Testing/Story-Xbztkyjilgeldprouohp6o.html">https://Www.Hindustantimes.Com/India-News/Iisc-Comes-up-with-an-Affordable-Two-Step-Method-to-Scale-up-Rt-Pcr-Testing/Story-Xbztkyjilgeldprouohp6o.html</ext-link></p></fn><fn id="footnote15"><label>15</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Hindustantimes.Com/Health/Indian-Trials-on-Multiple-Covid-19-Drugs-Make-Progress-Have-Atmanirbhar-Bharat-Tilt/Story-Nk0owrrrsyragqhvrk2a9i.html">https://Www.Hindustantimes.Com/Health/Indian-Trials-on-Multiple-Covid-19-Drugs-Make-Progress-Have-Atmanirbhar-Bharat-Tilt/Story-Nk0owrrrsyragqhvrk2a9i.html</ext-link></p></fn><fn id="footnote16"><label>16</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19</ext-link></p></fn><fn id="footnote17"><label>17</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Indialegallive.Com/Special-Story/Convalescent-Plasma-Therapy-a-Treatment-for-Covid-19/">https://Www.Indialegallive.Com/Special-Story/Convalescent-Plasma-Therapy-a-Treatment-for-Covid-19/</ext-link></p></fn><fn id="footnote18"><label>18</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Medrxiv.Org/Content/10.1101/2020.09.03.20187252v2">https://Www.Medrxiv.Org/Content/10.1101/2020.09.03.20187252v2</ext-link></p></fn><fn id="footnote19"><label>19</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Swachhindia.Ndtv.Com/Coronavirus-Outbreak-Explained-What-Is-Convalescent-Plasma-Therapy-and-How-Effective-Is-It-in-Treating-Covid-19-Patients-46568/">https://Swachhindia.Ndtv.Com/Coronavirus-Outbreak-Explained-What-Is-Convalescent-Plasma-Therapy-and-How-Effective-Is-It-in-Treating-Covid-19-Patients-46568/</ext-link></p></fn><fn id="footnote20"><label>20</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Thelancet.Com/Journals/Lanmic/Article/Piis2666-5247(20)30226-3/Fulltext">https://Www.Thelancet.Com/Journals/Lanmic/Article/Piis2666-5247(20)30226-3/Fulltext</ext-link></p></fn><fn id="footnote21"><label>21</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Thelancet.Com/Pdfs/Journals/Lanmic/Piis2666-5247(20)30226-3.Pdf">https://Www.Thelancet.Com/Pdfs/Journals/Lanmic/Piis2666-5247(20)30226-3.Pdf</ext-link></p></fn><fn id="footnote22"><label>22</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Indiatoday.In/News-Analysis/Story/Why-Covaxin-Covishield-Best-Option-for-India-against-Covid19-Pandemic-1755517-2021-01-03">https://Www.Indiatoday.In/News-Analysis/Story/Why-Covaxin-Covishield-Best-Option-for-India-against-Covid19-Pandemic-1755517-2021-01-03</ext-link></p></fn><fn id="footnote23"><label>23</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Thehindu.Com/Sci-Tech/Health/Uk-Becomes-First-Country-to-Approve-Astrazeneca-Oxford-Vaccine-for-Covid-19/Article33451081.Ece">https://Www.Thehindu.Com/Sci-Tech/Health/Uk-Becomes-First-Country-to-Approve-Astrazeneca-Oxford-Vaccine-for-Covid-19/Article33451081.Ece</ext-link></p></fn><fn id="footnote24"><label>24</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Businesstoday.In/Coronavirus/Oxford-Serum-Institute-Vaccine-Stored-Fridge-Temperature-2-8-Degrees/Story/422741.html">https://Www.Businesstoday.In/Coronavirus/Oxford-Serum-Institute-Vaccine-Stored-Fridge-Temperature-2-8-Degrees/Story/422741.html</ext-link></p></fn><fn id="footnote25"><label>25</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sputnikvaccine.com/about-vaccine/">https://sputnikvaccine.com/about-vaccine/</ext-link></p></fn><fn id="footnote26"><label>26</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://health.economictimes.indiatimes.com/news/pharma/serum-institute-conducting-phase-iii-clinical-trial-of-tuberculosis-vaccine-dbt/77210270">https://health.economictimes.indiatimes.com/news/pharma/serum-institute-conducting-phase-iii-clinical-trial-of-tuberculosis-vaccine-dbt/77210270</ext-link></p></fn><fn id="footnote27"><label>27</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pfizer.com/news/hot-topics/covid_19_vaccine_u_s_distribution_fact_sheet">https://www.pfizer.com/news/hot-topics/covid_19_vaccine_u_s_distribution_fact_sheet</ext-link></p></fn><fn id="footnote28"><label>28</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://indianexpress.com/article/explained/covid-19-vaccine-storage-optimal-temperature-cold-chain-india-explained-quixplained-7063369/">https://indianexpress.com/article/explained/covid-19-vaccine-storage-optimal-temperature-cold-chain-india-explained-quixplained-7063369/</ext-link></p></fn><fn id="footnote29"><label>29</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Health.Economictimes.Indiatimes.Com/News/Pharma/Ramping-up-Cold-Storage-Facilities-Critical-as-India-Preps-for-Covid-19-Vaccine-Experts/78550153">https://Health.Economictimes.Indiatimes.Com/News/Pharma/Ramping-up-Cold-Storage-Facilities-Critical-as-India-Preps-for-Covid-19-Vaccine-Experts/78550153</ext-link></p></fn><fn id="footnote30"><label>30</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Who.Int/Emergencies/Diseases/Novel-Coronavirus-2019/Covid-19-Vaccines">https://Www.Who.Int/Emergencies/Diseases/Novel-Coronavirus-2019/Covid-19-Vaccines</ext-link></p></fn><fn id="footnote31"><label>31</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Livemint.Com/Budget/News/Govt-Will-Bear-the-Entire-Cost-of-Covid-19-Vaccination-Guleria-11608563339012.html">https://Www.Livemint.Com/Budget/News/Govt-Will-Bear-the-Entire-Cost-of-Covid-19-Vaccination-Guleria-11608563339012.html</ext-link></p></fn><fn id="footnote32"><label>32</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Science.Thewire.In/Health/India-Covid-19-Vaccine-First-Phase-1-8-Billion/">https://Science.Thewire.In/Health/India-Covid-19-Vaccine-First-Phase-1-8-Billion/</ext-link></p></fn><fn id="footnote33"><label>33</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://indianexpress.com/article/explained/coronavirus-vaccines-india-covishield-bharat-biotech-covaxin-7131057/">https://indianexpress.com/article/explained/coronavirus-vaccines-india-covishield-bharat-biotech-covaxin-7131057/</ext-link></p></fn><fn id="footnote34"><label>34</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Timesofindia.Indiatimes.Com/Life-Style/Health-Fitness/Health-News/Coronavirus-Vaccine-Can-India-Get-Its-Hands-on-Modernas-Covid-19-Vaccine-3-Challenges-We-Have/Photostory/79411299.Cms?Picid=79411390">https://Timesofindia.Indiatimes.Com/Life-Style/Health-Fitness/Health-News/Coronavirus-Vaccine-Can-India-Get-Its-Hands-on-Modernas-Covid-19-Vaccine-3-Challenges-We-Have/Photostory/79411299.Cms?Picid=79411390</ext-link></p></fn><fn id="footnote35"><label>35</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Livemint.Com/News/India/India-S-Covid-19-Vaccination-Drive-to-Start-Soon-Registrations-Details-to-Guidelines-All-You-Need-to-Know-11608363252706.html">https://Www.Livemint.Com/News/India/India-S-Covid-19-Vaccination-Drive-to-Start-Soon-Registrations-Details-to-Guidelines-All-You-Need-to-Know-11608363252706.html</ext-link></p></fn><fn id="footnote36"><label>36</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.health.state.mn.us/facilities/patientsafety/infectioncontrol/ppe/index.html">https://www.health.state.mn.us/facilities/patientsafety/infectioncontrol/ppe/index.html</ext-link></p></fn><fn id="footnote37"><label>37</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.investindia.gov.in/siru/personal-protective-equipment-india-INR-7000-cr-industry-in-the-making">https://www.investindia.gov.in/siru/personal-protective-equipment-india-INR-7000-cr-industry-in-the-making</ext-link></p></fn><fn id="footnote38"><label>38</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Igi-Global.Com/Chapter/Fundamentals-of-Electrostatic-Spraying/232957">https://Www.Igi-Global.Com/Chapter/Fundamentals-of-Electrostatic-Spraying/232957</ext-link></p></fn><fn id="footnote39"><label>39</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Tribuneindia.Com/News/Nation/Csio-Develops-Electrostatic-Disinfection-Technology-to-Combat-Covid-78098">https://Www.Tribuneindia.Com/News/Nation/Csio-Develops-Electrostatic-Disinfection-Technology-to-Combat-Covid-78098</ext-link></p></fn><fn id="footnote40"><label>40</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Pib.Gov.In/Pressreleasepage.Aspx?Prid=1620351">https://Pib.Gov.In/Pressreleasepage.Aspx?Prid=1620351</ext-link></p></fn><fn id="footnote41"><label>41</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Medrxiv.Org/Content/10.1101/2020.03.26.20044511v1.Full.Pdf">https://Www.Medrxiv.Org/Content/10.1101/2020.03.26.20044511v1.Full.Pdf</ext-link></p></fn><fn id="footnote42"><label>42</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Tribuneindia.Com/News/Nation/Rail-Coach-Factory-Kapurthala-Develops-Ventilator-66118">https://Www.Tribuneindia.Com/News/Nation/Rail-Coach-Factory-Kapurthala-Develops-Ventilator-66118</ext-link></p></fn><fn id="footnote43"><label>43</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://Www.Csir.Res.In/Csir-Labs-Initiatives-against-Covid-19">https://Www.Csir.Res.In/Csir-Labs-Initiatives-against-Covid-19</ext-link></p></fn><fn id="footnote44"><label>44</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ayush.gov.in/">https://www.ayush.gov.in/</ext-link></p></fn><fn id="footnote45"><label>45</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://newsonair.nic.in/News?Title=Ministry-of-Ayush%2c-Csir-Working-Together-on-Validating-Four-Ayush-Formulations-against-Covid-19&amp;Id=388575">https://Newsonair.Nic.In/News?Title=Ministry-of-Ayush%2c-Csir-Working-Together-on-Validating-Four-Ayush-Formulations-against-Covid-19&amp;Id=388575</ext-link> (accessed on June 22, 2020).</p></fn><fn id="footnote46"><label>46</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://timesofindia.indiatimes.com/life-style/health-fitness/home-remedies/covid-19-ministry-of-ayush-starts-clinical-trials-for-ashwagandha-and-4-other-ayurvedic-herbs-here-is-what-you-need-to-know/photostory/75692669.cms">https://timesofindia.indiatimes.com/life-style/health-fitness/home-remedies/covid-19-ministry-of-ayush-starts-clinical-trials-for-ashwagandha-and-4-other-ayurvedic-herbs-here-is-what-you-need-to-know/photostory/75692669.cms</ext-link></p></fn><fn id="footnote47"><label>47</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.hindustantimes.com/india-news/trials-for-4-ayush-formulations-against-covid-19-to-start-within-a-week-says-minister/story-XU9RsNDC3vLrFukt3gOApK.html">https://www.hindustantimes.com/india-news/trials-for-4-ayush-formulations-against-covid-19-to-start-within-a-week-says-minister/story-XU9RsNDC3vLrFukt3gOApK.html</ext-link></p></fn><fn id="footnote48"><label>48</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Aarogya_Setu">https://en.wikipedia.org/wiki/Aarogya_Setu</ext-link></p></fn><fn id="footnote49"><label>49</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://static.mygov.in/rest/s3fs-public/mygov_159056978751307401.pdf">https://static.mygov.in/rest/s3fs-public/mygov_159056978751307401.pdf</ext-link> (retrieved on June 23, 2020).</p></fn><fn id="footnote50"><label>50</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ndtv.com/india-news/arvind-kejriwal-launches-delhi-corona-app-for-information-on-availability-of-hospital-beds-in-delhi-2239276">https://www.ndtv.com/india-news/arvind-kejriwal-launches-delhi-corona-app-for-information-on-availability-of-hospital-beds-in-delhi-2239276</ext-link></p></fn><fn id="footnote51"><label>51</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://indianexpress.com/article/explained/delhi-corona-mobile-application-covid-19-6438796/">https://indianexpress.com/article/explained/delhi-corona-mobile-application-covid-19-6438796/</ext-link></p></fn><fn id="footnote52"><label>52</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.thehindu.com/News/Cities/Delhi/Kejriwal-Launches-Delhi-Corona-App-for-Real-Time-Information-on-Availability-of-Hospital-Beds/Article31729239.Ece">https://Www.Thehindu.Com/News/Cities/Delhi/Kejriwal-Launches-Delhi-Corona-App-for-Real-Time-Information-on-Availability-of-Hospital-Beds/Article31729239.Ece</ext-link> (retrieved on June 23, 2020).</p></fn><fn id="footnote53"><label>53</label><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.Thehindu.Com/Sci-Tech/Health/the-Hindu-Explains-What-Are-the-Long-Term-Effects-of-Covid-19/Article32651206.Ece">https://www.Thehindu.Com/Sci-Tech/Health/the-Hindu-Explains-What-Are-the-Long-Term-Effects-of-Covid-19/Article32651206.Ece</ext-link></p></fn></fn-group><sec id="S9" sec-type="supplementary material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2021.637362/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2021.637362/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Data_Sheet_1.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnihotri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wakode</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Antimicrobial activity of essential oil and various extracts of fruits of greater cardamom.</article-title><source><italic toggle="yes">Indian J. Pharm. Sci.</italic></source><volume>72</volume><fpage>657</fpage>&#8211;<lpage>659</lpage>. <pub-id pub-id-type="doi">10.4103/0250-474x.78542</pub-id><pub-id pub-id-type="pmid">21695005</pub-id><pub-id pub-id-type="pmcid">PMC3116318</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Ventilator politics&#8212;the big picture.</article-title><source><italic toggle="yes">Indian J. Neurotrauma</italic></source><volume>17</volume><fpage>1</fpage>&#8211;<lpage>2</lpage>.</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>U.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>R.</given-names></name><name name-style="western"><surname>Udwadia</surname><given-names>Z. F.</given-names></name></person-group> (<year>2020</year>). <article-title>Favipiravir: a new and emerging antiviral option in COVID-19.</article-title><source><italic toggle="yes">Med. J. Armed Forces India</italic></source><volume>76</volume><fpage>370</fpage>&#8211;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1016/j.mjafi.2020.08.004</pub-id><pub-id pub-id-type="pmid">32895599</pub-id><pub-id pub-id-type="pmcid">PMC7467067</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahuja</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>V. P.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>O.</given-names></name></person-group> (<year>2020</year>). <article-title>Artificial intelligence and COVID-19: a multidisciplinary approach.</article-title><source><italic toggle="yes">Integr. Med. Res.</italic></source><volume>9</volume>:<issue>100434</issue>. <pub-id pub-id-type="doi">10.1016/j.imr.2020.100434</pub-id><pub-id pub-id-type="pmcid">PMC7255319</pub-id><pub-id pub-id-type="pmid">32632356</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tahir</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>S. M. A.</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Altaf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: a systematic review.</article-title><source><italic toggle="yes">Phytother. Res.</italic></source><volume>32</volume><fpage>811</fpage>&#8211;<lpage>822</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6024</pub-id><pub-id pub-id-type="pmid">29356205</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alagarasu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Choudhary</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Lole</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Potdar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Team</surname><given-names>N. I. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Evaluation of RdRp &amp; ORF-1b-nsp14-based real-time RT-PCR assays for confirmation of SARS-CoV-2 infection: an observational study.</article-title><source><italic toggle="yes">Indian J. Med. Res.</italic></source><volume>151</volume><fpage>483</fpage>&#8211;<lpage>485</lpage>.<pub-id pub-id-type="pmid">32474555</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijmr.IJMR_1256_20</pub-id><pub-id pub-id-type="pmcid">PMC7530456</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alimadadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aryal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manandhar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Munroe</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Joe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Artificial intelligence and machine learning to fight COVID-19.</article-title><source><italic toggle="yes">Physiol. Genomics</italic></source><volume>52</volume><fpage>200</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1152/physiolgenomics.00029.2020</pub-id><pub-id pub-id-type="pmid">32216577</pub-id><pub-id pub-id-type="pmcid">PMC7191426</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lipkin</surname><given-names>W. I.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Garry</surname><given-names>R. F.</given-names></name></person-group> (<year>2020</year>). <article-title>The proximal origin of SARS-CoV-2.</article-title><source><italic toggle="yes">Nat. Med.</italic></source><volume>26</volume>, <fpage>450</fpage>&#8211;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmid">32284615</pub-id><pub-id pub-id-type="pmcid">PMC7095063</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azkur</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Akdis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Azkur</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sokolowska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van De Veen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bruggen</surname><given-names>M. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.</article-title><source><italic toggle="yes">Allergy</italic></source><volume>75</volume><fpage>1564</fpage>&#8211;<lpage>1581</lpage>. <pub-id pub-id-type="doi">10.1111/all.14364</pub-id><pub-id pub-id-type="pmid">32396996</pub-id><pub-id pub-id-type="pmcid">PMC7272948</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.</article-title><source><italic toggle="yes">N. Engl. J. Med.</italic></source><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bairwa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sodha</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Rajawat</surname><given-names>B. S.</given-names></name></person-group> (<year>2012</year>). <article-title>Trachyspermum ammi.</article-title><source><italic toggle="yes">Pharmacogn. Rev.</italic></source><volume>6</volume><fpage>56</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.4103/0973-7847.95871</pub-id><pub-id pub-id-type="pmid">22654405</pub-id><pub-id pub-id-type="pmcid">PMC3358968</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balachandar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mahalaxmi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Devi</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Kaavya</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Laldinmawii</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Follow-up studies in COVID-19 recovered patients - is it mandatory?</article-title><source><italic toggle="yes">Sci. Total Environ.</italic></source><volume>729</volume>:<issue>139021</issue>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.139021</pub-id><pub-id pub-id-type="pmid">32360909</pub-id><pub-id pub-id-type="pmcid">PMC7184970</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biswas</surname><given-names>N. K.</given-names></name><name name-style="western"><surname>Majumder</surname><given-names>P. P.</given-names></name></person-group> (<year>2020</year>). <article-title>Analysis of RNA sequences of 3636 SARS-CoV-2 collected from 55 countries reveals selective sweep of one virus type.</article-title><source><italic toggle="yes">Indian J. Med. Res.</italic></source><volume>151</volume><fpage>450</fpage>&#8211;<lpage>458</lpage>. <pub-id pub-id-type="doi">10.4103/ijmr.ijmr_1125_20</pub-id><pub-id pub-id-type="pmid">32474553</pub-id><pub-id pub-id-type="pmcid">PMC7530441</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolhassani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khavari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bathaie</surname><given-names>S. Z.</given-names></name></person-group> (<year>2014</year>). <article-title>Saffron and natural carotenoids: biochemical activities and anti-tumor effects.</article-title><source><italic toggle="yes">Biochim. Biophys. Acta</italic></source><volume>1845</volume><fpage>20</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbcan.2013.11.001</pub-id><pub-id pub-id-type="pmid">24269582</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boskabady</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Alizadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jahanbin</surname><given-names>B.</given-names></name></person-group> (<year>2007</year>). <article-title>Bronchodilatory effect of Carum copticum in airways of asthmatic patients.</article-title><source><italic toggle="yes">Therapie</italic></source><volume>62</volume><fpage>23</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.2515/therapie:2007007</pub-id><pub-id pub-id-type="pmid">17374344</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boskabady</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Jandaghi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kiani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hasanzadeh</surname><given-names>L.</given-names></name></person-group> (<year>2005</year>). <article-title>Antitussive effect of Carum copticum in guinea pigs.</article-title><source><italic toggle="yes">J. Ethnopharmacol.</italic></source><volume>97</volume><fpage>79</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2004.10.016</pub-id><pub-id pub-id-type="pmid">15652279</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bragazzi</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Damiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Behzadifar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>How Big Data and Artificial intelligence can help better manage the COVID-19 pandemic.</article-title><source><italic toggle="yes">Int. J. Environ. Res. Public Health</italic></source><volume>17</volume>:<issue>3176</issue>. <pub-id pub-id-type="doi">10.3390/ijerph17093176</pub-id><pub-id pub-id-type="pmid">32370204</pub-id><pub-id pub-id-type="pmcid">PMC7246824</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Verheije</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Van Kuppeveld</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Rottier</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>B. J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>89</volume><fpage>4434</fpage>&#8211;<lpage>4448</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.03274-14</pub-id><pub-id pub-id-type="pmid">25653449</pub-id><pub-id pub-id-type="pmcid">PMC4442369</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>R. Y.</given-names></name><name name-style="western"><surname>To</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C. P.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">J. Infect.</italic></source><volume>67</volume><fpage>606</fpage>&#8211;<lpage>616</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2013.09.029</pub-id><pub-id pub-id-type="pmid">24096239</pub-id><pub-id pub-id-type="pmcid">PMC7112612</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset.</article-title><source><italic toggle="yes">J. Infect. Dis.</italic></source><volume>212</volume><fpage>1904</fpage>&#8211;<lpage>1913</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv392</pub-id><pub-id pub-id-type="pmid">26198719</pub-id><pub-id pub-id-type="pmcid">PMC7107395</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical and immunological features of severe and moderate coronavirus disease 2019.</article-title><source><italic toggle="yes">J. Clin. Invest.</italic></source><volume>130</volume><fpage>2620</fpage>&#8211;<lpage>2629</lpage>. <pub-id pub-id-type="doi">10.1172/jci137244</pub-id><pub-id pub-id-type="pmid">32217835</pub-id><pub-id pub-id-type="pmcid">PMC7190990</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>I. Y.</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Ichinohe</surname><given-names>T.</given-names></name></person-group> (<year>2019</year>). <article-title>Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome.</article-title><source><italic toggle="yes">Front. Microbiol.</italic></source><volume>10</volume>:<issue>50</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2019.00050</pub-id><pub-id pub-id-type="pmid">30761102</pub-id><pub-id pub-id-type="pmcid">PMC6361828</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhary</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Vipat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jadhav</surname><given-names>S.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cherian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India.</article-title><source><italic toggle="yes">Indian J. Med. Res.</italic></source><volume>151</volume><fpage>251</fpage>&#8211;<lpage>254</lpage>.<pub-id pub-id-type="pmid">32242876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijmr.IJMR_671_20</pub-id><pub-id pub-id-type="pmcid">PMC7224626</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhary</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.</article-title><source><italic toggle="yes">New Microbes New Infect.</italic></source><volume>35</volume><issue>100684</issue>. <pub-id pub-id-type="doi">10.1016/j.nmni.2020.100684</pub-id><pub-id pub-id-type="pmid">32322397</pub-id><pub-id pub-id-type="pmcid">PMC7175902</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>V. C.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>I. F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.</article-title><source><italic toggle="yes">Thorax</italic></source><volume>59</volume><fpage>252</fpage>&#8211;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1136/thorax.2003.012658</pub-id><pub-id pub-id-type="pmid">14985565</pub-id><pub-id pub-id-type="pmcid">PMC1746980</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cinatl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morgenstern</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rabenau</surname><given-names>H.</given-names></name><name name-style="western"><surname>Doerr</surname><given-names>H. W.</given-names></name></person-group> (<year>2003a</year>). <article-title>Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>361</volume><fpage>2045</fpage>&#8211;<lpage>2046</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(03)13615-x</pub-id><pub-id pub-id-type="pmid">12814717</pub-id><pub-id pub-id-type="pmcid">PMC7112442</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cinatl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morgenstern</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rabenau</surname><given-names>H.</given-names></name><name name-style="western"><surname>Doerr</surname><given-names>H. W.</given-names></name></person-group> (<year>2003b</year>). <article-title>Treatment of SARS with human interferons.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>362</volume><fpage>293</fpage>&#8211;<lpage>294</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(03)13973-6</pub-id><pub-id pub-id-type="pmid">12892961</pub-id><pub-id pub-id-type="pmcid">PMC7112413</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coriolano</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>De Santana Brito</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Siqueira Patriota</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>De Araujo Soares</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>De Lorena</surname><given-names>V. M. B.</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>P. M. G.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Immunomodulatory effects of the water-soluble lectin from <italic toggle="yes">Moringa oleifera</italic> seeds (WSMoL) on human peripheral blood mononuclear cells (PBMC).</article-title><source><italic toggle="yes">Protein Pept. Lett.</italic></source><volume>25</volume><fpage>295</fpage>&#8211;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.2174/0929866525666180130141736</pub-id><pub-id pub-id-type="pmid">29384049</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corman</surname><given-names>V. M.</given-names></name><name name-style="western"><surname>Landt</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molenkamp</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.</article-title><source><italic toggle="yes">Eur. Surveill.</italic></source><volume>25</volume>:<issue>2000045</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2020.25.3.2000045</pub-id><pub-id pub-id-type="pmcid">PMC6988269</pub-id><pub-id pub-id-type="pmid">31992387</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortegiani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ingoglia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ippolito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giarratano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Einav</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.</article-title><source><italic toggle="yes">J. Crit. Care</italic></source><volume>57</volume><fpage>279</fpage>&#8211;<lpage>283</lpage>.<pub-id pub-id-type="pmid">32173110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2020.03.005</pub-id><pub-id pub-id-type="pmcid">PMC7270792</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z. L.</given-names></name></person-group> (<year>2019</year>). <article-title>Origin and evolution of pathogenic coronaviruses.</article-title><source><italic toggle="yes">Nat. Rev. Microbiol.</italic></source><volume>17</volume><fpage>181</fpage>&#8211;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id><pub-id pub-id-type="pmid">30531947</pub-id><pub-id pub-id-type="pmcid">PMC7097006</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damle</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vourvahis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leaney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Corrigan</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19.</article-title><source><italic toggle="yes">Clin. Pharmacol. Ther.</italic></source><volume>108</volume><fpage>201</fpage>&#8211;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1002/cpt.1857</pub-id><pub-id pub-id-type="pmid">32302411</pub-id><pub-id pub-id-type="pmcid">PMC7262099</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darzi</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Khazraei</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Amirghofran</surname><given-names>Z.</given-names></name></person-group> (<year>2018</year>). <article-title>The immunoinhibitory and apoptosis-inducing activities of Foeniculum vulgare on human peripheral blood lymphocytes.</article-title><source><italic toggle="yes">Res. Pharm. Sci.</italic></source><volume>13</volume><fpage>103</fpage>&#8211;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.4103/1735-5362.223792</pub-id><pub-id pub-id-type="pmid">29606964</pub-id><pub-id pub-id-type="pmcid">PMC5842481</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wilde</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Jochmans</surname><given-names>D.</given-names></name><name name-style="western"><surname>Posthuma</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Zevenhoven-Dobbe</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Van Nieuwkoop</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T. M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.</article-title><source><italic toggle="yes">Antimicrob. Agents Chemother.</italic></source><volume>58</volume><fpage>4875</fpage>&#8211;<lpage>4884</lpage>. <pub-id pub-id-type="doi">10.1128/aac.03011-14</pub-id><pub-id pub-id-type="pmid">24841269</pub-id><pub-id pub-id-type="pmcid">PMC4136071</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karthik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khandia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Munjal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Medicinal and therapeutic potential of herbs and plant metabolites / extracts countering viral pathogens - current knowledge and future prospects.</article-title><source><italic toggle="yes">Curr. Drug Metab.</italic></source><volume>19</volume><fpage>236</fpage>&#8211;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.2174/1389200219666180129145252</pub-id><pub-id pub-id-type="pmid">29380697</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sachan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khandia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Munjal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>H. M. N.</given-names></name><name name-style="western"><surname>Latheef</surname><given-names>S. K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Medicinal and beneficial health applications of <italic toggle="yes">Tinospora cordifolia</italic> (Guduchi): a miraculous herb countering various diseases/disorders and its immunomodulatory effects.</article-title><source><italic toggle="yes">Recent Pat. Endocr. Metab. Immune Drug Discov.</italic></source><volume>10</volume><fpage>96</fpage>&#8211;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.2174/1872214811666170301105101</pub-id><pub-id pub-id-type="pmid">28260522</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The role of imaging in the detection and management of COVID-19: a review.</article-title><source><italic toggle="yes">IEEE Rev. Biomed. Eng.</italic></source><pub-id pub-id-type="doi">10.1109/RBME.2020.2990959</pub-id><comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">32356760</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S.A.</italic></source><volume>117</volume><fpage>9490</fpage>&#8211;<lpage>9496</lpage>.<pub-id pub-id-type="pmid">32253318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2004168117</pub-id><pub-id pub-id-type="pmcid">PMC7196837</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duncan</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Ayache</surname><given-names>N.</given-names></name></person-group> (<year>2000</year>). <article-title>Medical image analysis: progress over two decades and the challenges ahead.</article-title><source><italic toggle="yes">IEEE Trans. Pattern Anal. Machine Intell.</italic></source><volume>22</volume><fpage>85</fpage>&#8211;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1109/34.824822</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feinmann</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>PPE: what now for the global supply chain?</article-title><source><italic toggle="yes">BMJ</italic></source><volume>369</volume>:<issue>m1910</issue>. <pub-id pub-id-type="doi">10.1136/bmj.m1910</pub-id><pub-id pub-id-type="pmid">32414747</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y. D.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F. F.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>A review on traditional uses, phytochemistry and pharmacology of <italic toggle="yes">Eclipta prostrata</italic> (L.) L.</article-title><source><italic toggle="yes">J. Ethnopharmacol.</italic></source><volume>245</volume>:<issue>112109</issue>. <pub-id pub-id-type="doi">10.1016/j.jep.2019.112109</pub-id><pub-id pub-id-type="pmid">31395303</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>11</volume>:<issue>4968</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-18786-x</pub-id><pub-id pub-id-type="pmcid">PMC7532528</pub-id><pub-id pub-id-type="pmid">33009413</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferner</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Aronson</surname><given-names>J. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Remdesivir in covid-19.</article-title><source><italic toggle="yes">BMJ</italic></source><volume>369</volume>:<issue>m1610</issue>. <pub-id pub-id-type="doi">10.1136/bmj.m1610</pub-id><pub-id pub-id-type="pmid">32321732</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>396</volume><fpage>467</fpage>&#8211;<lpage>478</lpage>.<pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fouladi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Masjedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ganjalikhani Hakemi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eskandari</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>). <article-title>The review of in vitro and in vivo studies over the glycyrrhizic acid as natural remedy option for treatment of allergic asthma.</article-title><source><italic toggle="yes">Iran J Allergy Asthma Immunol.</italic></source><volume>18</volume><fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">30848569</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gowen</surname><given-names>B. B.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shiraki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Smee</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Favipiravir (T-705), a novel viral RNA polymerase inhibitor.</article-title><source><italic toggle="yes">Antiviral Res.</italic></source><volume>100</volume><fpage>446</fpage>&#8211;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.09.015</pub-id><pub-id pub-id-type="pmid">24084488</pub-id><pub-id pub-id-type="pmcid">PMC3880838</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gautret</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lagier</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Parola</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>V. T.</given-names></name><name name-style="western"><surname>Meddeb</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mailhe</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.</article-title><source><italic toggle="yes">Int. J. Antimicrob. Agents</italic></source><volume>56</volume>:<issue>105949</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2020.105949</pub-id><pub-id pub-id-type="pmcid">PMC7102549</pub-id><pub-id pub-id-type="pmid">32205204</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11718083"/></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholamnezhad</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Havakhah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boskabady</surname><given-names>M. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: a review.</article-title><source><italic toggle="yes">J. Ethnopharmacol.</italic></source><volume>190</volume><fpage>372</fpage>&#8211;<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2016.06.061</pub-id><pub-id pub-id-type="pmid">27364039</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholamnezhad</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shakeri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Saadat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghorani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Boskabady</surname><given-names>M. H.</given-names></name></person-group> (<year>2019</year>). <article-title>Clinical and experimental effects of Nigella sativa and its constituents on respiratory and allergic disorders.</article-title><source><italic toggle="yes">Avicenna J. Phytomed.</italic></source><volume>9</volume><fpage>195</fpage>&#8211;<lpage>212</lpage>.<pub-id pub-id-type="pmid">31143688</pub-id><pub-id pub-id-type="pmcid">PMC6526035</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Bouhaddou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Obernier</surname><given-names>K.</given-names></name><name name-style="western"><surname>White</surname><given-names>K. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.</article-title><source><italic toggle="yes">Nature</italic></source><volume>583</volume><fpage>459</fpage>&#8211;<lpage>468</lpage>.<pub-id pub-id-type="pmid">32353859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2286-9</pub-id><pub-id pub-id-type="pmcid">PMC7431030</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Potdar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Praharaj</surname><given-names>I.</given-names></name><name name-style="western"><surname>Giri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Laboratory preparedness for SARS-CoV-2 testing in India: harnessing a network of virus research &amp; diagnostic laboratories.</article-title><source><italic toggle="yes">Indian J. Med. Res.</italic></source><volume>151</volume><fpage>216</fpage>&#8211;<lpage>225</lpage>.<pub-id pub-id-type="pmid">32242875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijmr.IJMR_594_20</pub-id><pub-id pub-id-type="pmcid">PMC7258754</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Beaumont</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>). <article-title>Chemical composition analysis and in vitro biological activities of ten essential oils in human skin cells.</article-title><source><italic toggle="yes">Biochim. Open</italic></source><volume>5</volume><fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopen.2017.04.001</pub-id><pub-id pub-id-type="pmid">29450150</pub-id><pub-id pub-id-type="pmcid">PMC5805555</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Neem components as potential agents for cancer prevention and treatment.</article-title><source><italic toggle="yes">Biochim. Biophys. Acta</italic></source><volume>1846</volume><fpage>247</fpage>&#8211;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbcan.2014.07.002</pub-id><pub-id pub-id-type="pmid">25016141</pub-id><pub-id pub-id-type="pmcid">PMC4734358</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Jantan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Abbas Bukhari</surname><given-names>S. N.</given-names></name></person-group> (<year>2017</year>). <article-title>Tinospora species: an overview of their modulating effects on the immune system.</article-title><source><italic toggle="yes">J. Ethnopharmacol.</italic></source><volume>207</volume><fpage>67</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2017.06.013</pub-id><pub-id pub-id-type="pmid">28629816</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Immediate and long-term consequences of COVID-19 infections for the development of neurological disease.</article-title><source><italic toggle="yes">Alzheimers Res. Ther.</italic></source><volume>12</volume>:<issue>69</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00640-3</pub-id><pub-id pub-id-type="pmcid">PMC7271826</pub-id><pub-id pub-id-type="pmid">32498691</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erichsen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.</article-title><source><italic toggle="yes">Cell</italic></source><volume>181</volume><fpage>271</fpage>&#8211;<lpage>280.e278</lpage>.<pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Detection of IgM and IgG antibodies in patients with coronavirus disease 2019.</article-title><source><italic toggle="yes">Clin. Transl. Immunol.</italic></source><volume>9</volume>:<issue>e01136</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cti2.1136</pub-id><pub-id pub-id-type="pmcid">PMC7202656</pub-id><pub-id pub-id-type="pmid">32382418</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>395</volume><fpage>497</fpage>&#8211;<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.</article-title><source><italic toggle="yes">Sci. Rep.</italic></source><volume>5</volume>:<issue>8528</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep08528</pub-id><pub-id pub-id-type="pmcid">PMC4336931</pub-id><pub-id pub-id-type="pmid">25704206</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I. N.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Andrographolide, a diterpene lactone from <italic toggle="yes">Andrographis paniculata</italic> and its therapeutic promises in cancer.</article-title><source><italic toggle="yes">Cancer Lett.</italic></source><volume>420</volume><fpage>129</fpage>&#8211;<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2018.01.074</pub-id><pub-id pub-id-type="pmid">29408515</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iyengar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bahl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vaishya</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vaish</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Challenges and solutions in meeting up the urgent requirement of ventilators for COVID-19 patients.</article-title><source><italic toggle="yes">Diabetes Metab. Syndr. Clin. Res. Rev.</italic></source><volume>14</volume><fpage>499</fpage>&#8211;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1016/j.dsx.2020.04.048</pub-id><pub-id pub-id-type="pmid">32388328</pub-id><pub-id pub-id-type="pmcid">PMC7198404</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jayaramayya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Dayem</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S. G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19: an update on diagnostic and therapeutic approaches.</article-title><source><italic toggle="yes">BMB Rep.</italic></source><volume>53</volume><fpage>191</fpage>&#8211;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.5483/bmbrep.2020.53.4.080</pub-id><pub-id pub-id-type="pmid">32336317</pub-id><pub-id pub-id-type="pmcid">PMC7196187</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jabbari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>). <article-title>Artificial intelligence and immunotherapy.</article-title><source><italic toggle="yes">Expert Rev. Clin. Immunol.</italic></source><volume>15</volume><fpage>689</fpage>&#8211;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1080/1744666x.2019.1623670</pub-id><pub-id pub-id-type="pmid">31157571</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L. K.</given-names></name><name name-style="western"><surname>Rajwanshi</surname><given-names>V. K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deval</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5&#8217;-triphosphate towards influenza A virus polymerase.</article-title><source><italic toggle="yes">PLoS One</italic></source><volume>8</volume>:<issue>e68347</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0068347</pub-id><pub-id pub-id-type="pmid">23874596</pub-id><pub-id pub-id-type="pmcid">PMC3707847</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahkhaie</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Mirhosseini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aliabadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Haftcheshmeh</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Curcumin: a modulator of inflammatory signaling pathways in the immune system.</article-title><source><italic toggle="yes">Inflammopharmacology</italic></source><volume>27</volume><fpage>885</fpage>&#8211;<lpage>900</lpage>. <pub-id pub-id-type="doi">10.1007/s10787-019-00607-3</pub-id><pub-id pub-id-type="pmid">31140036</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kampf</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential role of inanimate surfaces for the spread of coronaviruses and their inactivation with disinfectant agents.</article-title><source><italic toggle="yes">Infect. Prevention Pract.</italic></source><volume>2</volume>:<issue>100044</issue>. <pub-id pub-id-type="doi">10.1016/j.infpip.2020.100044</pub-id><pub-id pub-id-type="pmcid">PMC7148653</pub-id><pub-id pub-id-type="pmid">34316556</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kampf</surname><given-names>G.</given-names></name><name name-style="western"><surname>Todt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pfaender</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steinmann</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents.</article-title><source><italic toggle="yes">J. Hosp. Infect.</italic></source><volume>104</volume><fpage>246</fpage>&#8211;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhin.2020.01.022</pub-id><pub-id pub-id-type="pmid">32563551</pub-id><pub-id pub-id-type="pmcid">PMC7834866</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamyab</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Eshraghian</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Anti-Inflammatory, gastrointestinal and hepatoprotective effects of <italic toggle="yes">Ocimum sanctum</italic> Linn: an ancient remedy with new application.</article-title><source><italic toggle="yes">Inflamm. Allergy Drug Targets</italic></source><volume>12</volume><fpage>378</fpage>&#8211;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.2174/1871528112666131125110017</pub-id><pub-id pub-id-type="pmid">24266685</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandikattu</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Rachitha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jayashree</surname><given-names>G. V.</given-names></name><name name-style="western"><surname>Krupashree</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sukhith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Majid</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Anti-inflammatory and anti-oxidant effects of Cardamom (Elettaria repens (Sonn.) Baill) and its phytochemical analysis by 4D GCXGC TOF-MS.</article-title><source><italic toggle="yes">Biomed. Pharmacother.</italic></source><volume>91</volume><fpage>191</fpage>&#8211;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.04.049</pub-id><pub-id pub-id-type="pmid">28458157</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>N.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dar</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bijarnia</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Dhingra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2.</article-title><source><italic toggle="yes">Infect. Genet. Evol.</italic></source><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104490</pub-id><comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">32745811</pub-id><pub-id pub-id-type="pmcid">PMC7395230</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaushik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>J. P.</given-names></name></person-group> (<year>2020</year>). <article-title>The Indian perspective of COVID-19 outbreak.</article-title><source><italic toggle="yes">Virusdisease</italic></source><volume>31</volume><fpage>1</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32368570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13337-020-00587-x</pub-id><pub-id pub-id-type="pmcid">PMC7197250</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kamar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nemer</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Thalidomide-revisited: are COVID-19 patients going to be the latest victims of yet another theoretical drug-repurposing?</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>11</volume>:<issue>1248</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01248</pub-id><pub-id pub-id-type="pmid">32574274</pub-id><pub-id pub-id-type="pmcid">PMC7270289</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>F.</given-names></name><name name-style="western"><surname>Suri</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>Molecular insight into the immune up-regulatory properties of the leaf extract of Ashwagandha and identification of Th1 immunostimulatory chemical entity.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>27</volume><fpage>6080</fpage>&#8211;<lpage>6087</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.011</pub-id><pub-id pub-id-type="pmid">19628058</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khorsand</surname><given-names>B.</given-names></name><name name-style="western"><surname>Savadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naghibzadeh</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2-human protein-protein interaction network.</article-title><source><italic toggle="yes">Inform. Med. Unlocked</italic></source><volume>20</volume>:<issue>100413</issue>. <pub-id pub-id-type="doi">10.1016/j.imu.2020.100413</pub-id><pub-id pub-id-type="pmcid">PMC7425553</pub-id><pub-id pub-id-type="pmid">32838020</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>J. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential hazards of concern in the walk-through screening system for the corona virus disease 2019 from the perspective of infection preventionists.</article-title><source><italic toggle="yes">J. Korean Med. Sci.</italic></source><volume>35</volume>:<issue>e156</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3346/jkms.2020.35.e156</pub-id><pub-id pub-id-type="pmcid">PMC7167405</pub-id><pub-id pub-id-type="pmid">32301301</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kodali</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Hense</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kopparty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kalapala</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Haloi</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>How Indians responded to the Arogya Setu app?</article-title><source><italic toggle="yes">Indian J. Public Health</italic></source><volume>64</volume><fpage>S228</fpage>&#8211;<lpage>S230</lpage>.<pub-id pub-id-type="pmid">32496261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijph.IJPH_499_20</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Antitussive and expectorant activities of licorice and its major compounds.</article-title><source><italic toggle="yes">Bioorg. Med. Chem.</italic></source><volume>26</volume><fpage>278</fpage>&#8211;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2017.11.046</pub-id><pub-id pub-id-type="pmid">29224994</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamba</surname><given-names>I.</given-names></name></person-group> (<year>2020</year>). <article-title>Why India needs to extend the nationwide lockdown.</article-title><source><italic toggle="yes">Am. J. Emerg. Med.</italic></source><volume>38</volume><fpage>1528</fpage>&#8211;<lpage>1529</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajem.2020.04.026</pub-id><pub-id pub-id-type="pmid">32307297</pub-id><pub-id pub-id-type="pmcid">PMC7159851</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Andreadakis</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>G&#243;mez Rom&#225;n</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tollefsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The COVID-19 vaccine development landscape.</article-title><source><italic toggle="yes">Nat Rev. Drug Discov.</italic></source><volume>19</volume>, <fpage>305</fpage>&#8211;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1038/d41573-020-00073-5</pub-id><pub-id pub-id-type="pmid">32273591</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>O. K.</given-names></name><name name-style="western"><surname>Yuk</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Protective effects of neem (Azadirachta indica A. Juss.) leaf extract against cigarette smoke- and lipopolysaccharide-induced pulmonary inflammation.</article-title><source><italic toggle="yes">Int. J. Mol. Med.</italic></source><volume>40</volume><fpage>1932</fpage>&#8211;<lpage>1940</lpage>.<pub-id pub-id-type="pmid">29039495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2017.3178</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Pedone</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Curcumin use in pulmonary diseases: state of the art and future perspectives.</article-title><source><italic toggle="yes">Pharmacol. Res.</italic></source><volume>115</volume><fpage>133</fpage>&#8211;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2016.11.017</pub-id><pub-id pub-id-type="pmid">27888157</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lentini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cavalluzzi</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Habtemariam</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19, chloroquine repurposing, and cardiac safety concern: chirality might help.</article-title><source><italic toggle="yes">Molecules</italic></source><volume>25</volume>:<issue>1834</issue>. <pub-id pub-id-type="doi">10.3390/molecules25081834</pub-id><pub-id pub-id-type="pmid">32316270</pub-id><pub-id pub-id-type="pmcid">PMC7221598</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Using artificial intelligence to detect COVID-19 and community-acquired pneumonia based on pulmonary CT: evaluation of the diagnostic accuracy.</article-title><source><italic toggle="yes">Radiology</italic></source><volume>296</volume><fpage>E65</fpage>&#8211;<lpage>E71</lpage>.<pub-id pub-id-type="pmid">32191588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiol.2020200905</pub-id><pub-id pub-id-type="pmcid">PMC7233473</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chaudhry</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Quercetin, inflammation and immunity.</article-title><source><italic toggle="yes">Nutrients</italic></source><volume>8</volume>:<issue>167</issue>. <pub-id pub-id-type="doi">10.3390/nu8030167</pub-id><pub-id pub-id-type="pmid">26999194</pub-id><pub-id pub-id-type="pmcid">PMC4808895</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.</article-title><source><italic toggle="yes">Nat. Med.</italic></source><volume>26</volume><fpage>842</fpage>&#8211;<lpage>844</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id><pub-id pub-id-type="pmid">32398875</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kwok</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.</article-title><source><italic toggle="yes">JCI Insight</italic></source><volume>4</volume>:<issue>e123158</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.123158</pub-id><pub-id pub-id-type="pmcid">PMC6478436</pub-id><pub-id pub-id-type="pmid">30830861</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lotfi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>N.</given-names></name></person-group> (<year>2020</year>). <article-title>CRISPR/Cas13: a potential therapeutic option of COVID-19.</article-title><source><italic toggle="yes">Biomed. Pharmacother.</italic></source><volume>131</volume>:<issue>110738</issue>. <pub-id pub-id-type="doi">10.1016/j.biopha.2020.110738</pub-id><pub-id pub-id-type="pmid">33152914</pub-id><pub-id pub-id-type="pmcid">PMC7498250</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Tocilizumab treatment in COVID-19: a single center experience.</article-title><source><italic toggle="yes">J. Med. Virol.</italic></source><volume>92</volume><fpage>814</fpage>&#8211;<lpage>818</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25801</pub-id><pub-id pub-id-type="pmid">32253759</pub-id><pub-id pub-id-type="pmcid">PMC7262125</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyons</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Law</surname><given-names>S. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Electrostatic application of antimicrobial sprays to sanitize food handling and processing surfaces for enhanced food safety.</article-title><source><italic toggle="yes">J. Phys.</italic></source><volume>301</volume>:<issue>012014</issue>. <pub-id pub-id-type="doi">10.1088/1742-6596/301/1/012014</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mulvey</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nuovo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harp</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases.</article-title><source><italic toggle="yes">Transl. Res.</italic></source><volume>220</volume><fpage>1</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.trsl.2020.04.007</pub-id><pub-id pub-id-type="pmid">32299776</pub-id><pub-id pub-id-type="pmcid">PMC7158248</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majdalawieh</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>R. I.</given-names></name></person-group> (<year>2010</year>). <article-title>In vitro investigation of the potential immunomodulatory and anti-cancer activities of black pepper (<italic toggle="yes">Piper nigrum</italic>) and cardamom (<italic toggle="yes">Elettaria cardamomum</italic>).</article-title><source><italic toggle="yes">J. Med. Food</italic></source><volume>13</volume><fpage>371</fpage>&#8211;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1089/jmf.2009.1131</pub-id><pub-id pub-id-type="pmid">20210607</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majdalawieh</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Fayyad</surname><given-names>M. W.</given-names></name></person-group> (<year>2015</year>). <article-title>Immunomodulatory and anti-inflammatory action of <italic toggle="yes">Nigella sativa</italic> and thymoquinone: a comprehensive review.</article-title><source><italic toggle="yes">Int. Immunopharmacol.</italic></source><volume>28</volume><fpage>295</fpage>&#8211;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2015.06.023</pub-id><pub-id pub-id-type="pmid">26117430</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maji</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Pandit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Banerji</surname><given-names>P.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title><italic toggle="yes">Pueraria tuberosa</italic>: a review on its phytochemical and therapeutic potential.</article-title><source><italic toggle="yes">Nat. Prod. Res.</italic></source><volume>28</volume><fpage>2111</fpage>&#8211;<lpage>2127</lpage>. <pub-id pub-id-type="doi">10.1080/14786419.2014.928291</pub-id><pub-id pub-id-type="pmid">24980468</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manu</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Kuttan</surname><given-names>G.</given-names></name></person-group> (<year>2009</year>). <article-title>Immunomodulatory activities of Punarnavine, an alkaloid from <italic toggle="yes">Boerhaavia diffusa</italic>.</article-title><source><italic toggle="yes">Immunopharmacol. Immunotoxicol.</italic></source><volume>31</volume><fpage>377</fpage>&#8211;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1080/08923970802702036</pub-id><pub-id pub-id-type="pmid">19555203</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McBride</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>B. C.</given-names></name></person-group> (<year>2012</year>). <article-title>The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis.</article-title><source><italic toggle="yes">Viruses</italic></source><volume>4</volume><fpage>2902</fpage>&#8211;<lpage>2923</lpage>. <pub-id pub-id-type="doi">10.3390/v4112902</pub-id><pub-id pub-id-type="pmid">23202509</pub-id><pub-id pub-id-type="pmcid">PMC3509677</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mcauley</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tattersall</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Manson</surname><given-names>J. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19: consider cytokine storm syndromes and immunosuppression.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>395</volume><fpage>1033</fpage>&#8211;<lpage>1034</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)30628-0</pub-id><pub-id pub-id-type="pmid">32192578</pub-id><pub-id pub-id-type="pmcid">PMC7270045</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michot</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Albiges</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chaput</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saada</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pommeret</surname><given-names>F.</given-names></name><name name-style="western"><surname>Griscelli</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.</article-title><source><italic toggle="yes">Ann. Oncol.</italic></source><volume>31</volume><fpage>961</fpage>&#8211;<lpage>964</lpage>. <pub-id pub-id-type="doi">10.1016/j.annonc.2020.03.300</pub-id><pub-id pub-id-type="pmid">32247642</pub-id><pub-id pub-id-type="pmcid">PMC7136869</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aeri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gaur</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Jachak</surname><given-names>S. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Phytochemical, therapeutic, and ethnopharmacological overview for a traditionally important herb: <italic toggle="yes">Boerhavia diffusa</italic> Linn.</article-title><source><italic toggle="yes">Biomed. Res. Int.</italic></source><volume>2014</volume>:<issue>808302</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/808302</pub-id><pub-id pub-id-type="pmcid">PMC4053255</pub-id><pub-id pub-id-type="pmid">24949473</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohapatra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhadoria</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Kant</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Restricting rural-urban connect to combat infectious disease epidemic as India fights COVID-19.</article-title><source><italic toggle="yes">J. Family Med. Prim. Care</italic></source><volume>9</volume><fpage>1792</fpage>&#8211;<lpage>1794</lpage>. <pub-id pub-id-type="doi">10.4103/jfmpc.jfmpc_451_20</pub-id><pub-id pub-id-type="pmid">32670918</pub-id><pub-id pub-id-type="pmcid">PMC7346920</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Gayen</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 in India transmits from the urban to the rural.</article-title><source><italic toggle="yes">Int. J. Health Plann. Manage.</italic></source><volume>35</volume><fpage>1623</fpage>&#8211;<lpage>1625</lpage>. <pub-id pub-id-type="doi">10.1002/hpm.3047</pub-id><pub-id pub-id-type="pmid">32881038</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mittal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Surjit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soneja</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Gargle lavage as a viable alternative to swab for detection of SARS-CoV-2.</article-title><source><italic toggle="yes">Indian J. Med. Res.</italic></source><volume>152</volume><fpage>77</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.4103/ijmr.ijmr_2987_20</pub-id><pub-id pub-id-type="pmid">32820725</pub-id><pub-id pub-id-type="pmcid">PMC7853282</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohanraj</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karthikeyan</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Vivek-Ananth</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Chand</surname><given-names>R. P. B.</given-names></name><name name-style="western"><surname>Aparna</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Mangalapandi</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>IMPPAT: a curated database of Indian medicinal plants, phytochemistry and therapeutics.</article-title><source><italic toggle="yes">Sci. Rep.</italic></source><volume>8</volume>:<issue>4329</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-22631-z</pub-id><pub-id pub-id-type="pmcid">PMC5847565</pub-id><pub-id pub-id-type="pmid">29531263</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mondal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Varma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bamola</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Naik</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Mirdha</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Padhi</surname><given-names>M. M.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Double-blinded randomized controlled trial for immunomodulatory effects of Tulsi (Ocimum sanctum Linn.) leaf extract on healthy volunteers.</article-title><source><italic toggle="yes">J. Ethnopharmacol.</italic></source><volume>136</volume><fpage>452</fpage>&#8211;<lpage>456</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2011.05.012</pub-id><pub-id pub-id-type="pmid">21619917</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moshiri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vahabzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hosseinzadeh</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>Clinical applications of saffron (<italic toggle="yes">Crocus sativus</italic>) and its constituents: a review.</article-title><source><italic toggle="yes">Drug Res. (Stuttg)</italic></source><volume>65</volume><fpage>287</fpage>&#8211;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1055/s-0034-1375681</pub-id><pub-id pub-id-type="pmid">24848002</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mourya</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Sk</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Shete</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name></person-group> (<year>2020</year>). <article-title>Biorisk assessment for infrastructure &amp; biosafety requirements for the laboratories providing coronavirus SARS-CoV-2/(COVID-19) diagnosis.</article-title><source><italic toggle="yes">Indian J. Med. Res.</italic></source><volume>151</volume><fpage>172</fpage>&#8211;<lpage>176</lpage>.<pub-id pub-id-type="pmid">32242878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijmr.IJMR_763_20</pub-id><pub-id pub-id-type="pmcid">PMC7357401</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mousa</surname><given-names>H. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Prevention and Treatment of influenza, influenza-like illness, and common cold by herbal, complementary, and natural therapies.</article-title><source><italic toggle="yes">J. Evid. Based Complementary Altern. Med.</italic></source><volume>22</volume><fpage>166</fpage>&#8211;<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1177/2156587216641831</pub-id><pub-id pub-id-type="pmid">27055821</pub-id><pub-id pub-id-type="pmcid">PMC5871211</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narayanan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>SARS coronavirus accessory proteins.</article-title><source><italic toggle="yes">Virus Res.</italic></source><volume>133</volume><fpage>113</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.10.009</pub-id><pub-id pub-id-type="pmid">18045721</pub-id><pub-id pub-id-type="pmcid">PMC2720074</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nemetchek</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Stierle</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Stierle</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Lurie</surname><given-names>D. I.</given-names></name></person-group> (<year>2017</year>). <article-title>The Ayurvedic plant <italic toggle="yes">Bacopa monnieri</italic> inhibits inflammatory pathways in the brain.</article-title><source><italic toggle="yes">J. Ethnopharmacol.</italic></source><volume>197</volume><fpage>92</fpage>&#8211;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2016.07.073</pub-id><pub-id pub-id-type="pmid">27473605</pub-id><pub-id pub-id-type="pmcid">PMC5269610</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Dominguez-Andres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Chavakis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Divangahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Defining trained immunity and its role in health and disease.</article-title><source><italic toggle="yes">Nat. Rev. Immunol.</italic></source><volume>20</volume><fpage>375</fpage>&#8211;<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmid">32132681</pub-id><pub-id pub-id-type="pmcid">PMC7186935</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>K. N.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>G. K.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>P. Q.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Dedon</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>J. P.</given-names></name></person-group> (<year>2016</year>). <article-title>Immunostimulating and Gram-negative-specific antibacterial cyclotides from the butterfly pea (<italic toggle="yes">Clitoria ternatea</italic>).</article-title><source><italic toggle="yes">FEBS J.</italic></source><volume>283</volume><fpage>2067</fpage>&#8211;<lpage>2090</lpage>. <pub-id pub-id-type="doi">10.1111/febs.13720</pub-id><pub-id pub-id-type="pmid">27007913</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Deep learning COVID-19 features on CXR using limited training data sets.</article-title><source><italic toggle="yes">IEEE Trans. Med. Imaging</italic></source><volume>39</volume><fpage>2688</fpage>&#8211;<lpage>2700</lpage>. <pub-id pub-id-type="doi">10.1109/tmi.2020.2993291</pub-id><pub-id pub-id-type="pmid">32396075</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omolo</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fasiku</surname><given-names>V. O.</given-names></name><name name-style="western"><surname>Mackraj</surname><given-names>I.</given-names></name><name name-style="western"><surname>Govender</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus.</article-title><source><italic toggle="yes">Eur. J. Pharmacol.</italic></source><volume>883</volume>:<issue>173348</issue>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173348</pub-id><pub-id pub-id-type="pmcid">PMC7334944</pub-id><pub-id pub-id-type="pmid">32634438</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M. U.</given-names></name><name name-style="western"><surname>Huffman</surname><given-names>A.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>11</volume>:<issue>1581</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01581</pub-id><pub-id pub-id-type="pmid">32719684</pub-id><pub-id pub-id-type="pmcid">PMC7350702</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ose</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schink</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maxeiner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Cinnamon extract inhibits allergen-specific immune responses in human and murine allergy models.</article-title><source><italic toggle="yes">Clin. Exp. Allergy</italic></source><volume>50</volume><fpage>41</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1111/cea.13507</pub-id><pub-id pub-id-type="pmid">31573731</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Othman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bouslama</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Brandenburg</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>da Rocha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hamdi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ghedira</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.</article-title><source><italic toggle="yes">Biochem. Biophys. Res. Commun.</italic></source><volume>527</volume>, <fpage>702</fpage>&#8211;<lpage>708</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.05.028</pub-id><pub-id pub-id-type="pmid">32410735</pub-id><pub-id pub-id-type="pmcid">PMC7221370</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paital</surname><given-names>B.</given-names></name><name name-style="western"><surname>Das</surname><given-names>K.</given-names></name><name name-style="western"><surname>Parida</surname><given-names>S. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India.</article-title><source><italic toggle="yes">Sci. Total Environ.</italic></source><volume>728</volume>:<issue>138914</issue>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.138914</pub-id><pub-id pub-id-type="pmcid">PMC7179495</pub-id><pub-id pub-id-type="pmid">32339832</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Katara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rastogi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rawat</surname><given-names>A. K.</given-names></name></person-group> (<year>2013</year>). <article-title>An important Indian traditional drug of ayurveda jatamansi and its substitute bhootkeshi: chemical profiling and antioxidant activity.</article-title><source><italic toggle="yes">Evid. Based Complement Alternat. Med.</italic></source><volume>2013</volume>:<issue>142517</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/142517</pub-id><pub-id pub-id-type="pmcid">PMC3618914</pub-id><pub-id pub-id-type="pmid">23573115</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parray</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Chiranjivi</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mani</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a naive semisynthetic library.</article-title><source><italic toggle="yes">J. Biol. Chem.</italic></source><volume>295</volume><fpage>12814</fpage>&#8211;<lpage>12821</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.ac120.014918</pub-id><pub-id pub-id-type="pmid">32727845</pub-id><pub-id pub-id-type="pmcid">PMC7476711</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>C. T.</given-names></name><name name-style="western"><surname>Denniston</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Therapeutic uses of triphala in ayurvedic medicine.</article-title><source><italic toggle="yes">J. Altern. Complement Med.</italic></source><volume>23</volume><fpage>607</fpage>&#8211;<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1089/acm.2017.0083</pub-id><pub-id pub-id-type="pmid">28696777</pub-id><pub-id pub-id-type="pmcid">PMC5567597</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pise</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Rudra</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Immunomodulatory potential of shatavarins produced from <italic toggle="yes">Asparagus racemosus</italic> tissue cultures.</article-title><source><italic toggle="yes">J. Nat. Sci. Biol. Med.</italic></source><volume>6</volume><fpage>415</fpage>&#8211;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.4103/0976-9668.160025</pub-id><pub-id pub-id-type="pmid">26283842</pub-id><pub-id pub-id-type="pmcid">PMC4518422</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F. P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.</article-title><source><italic toggle="yes">N. Engl. J. Med.</italic></source><volume>383</volume><fpage>2603</fpage>&#8211;<lpage>2615</lpage>.<pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>M.</given-names></name><name name-style="western"><surname>An</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name></person-group> (<year>2019</year>). <article-title>Terrestrosin D from <italic toggle="yes">Tribulus terrestris</italic> attenuates bleomycin-induced inflammation and suppresses fibrotic changes in the lungs of mice.</article-title><source><italic toggle="yes">Pharm. Biol.</italic></source><volume>57</volume><fpage>694</fpage>&#8211;<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1080/13880209.2019.1672754</pub-id><pub-id pub-id-type="pmid">31608748</pub-id><pub-id pub-id-type="pmcid">PMC6807862</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rai</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Birla</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zahra</surname><given-names>W.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Immunomodulation of Parkinson&#8217;s disease using <italic toggle="yes">Mucuna pruriens</italic> (Mp).</article-title><source><italic toggle="yes">J. Chem. Neuroanat.</italic></source><volume>85</volume><fpage>27</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.jchemneu.2017.06.005</pub-id><pub-id pub-id-type="pmid">28642128</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Randhawa</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Soltysiak</surname><given-names>M. P. M.</given-names></name><name name-style="western"><surname>El Roz</surname><given-names>H.</given-names></name><name name-style="western"><surname>De Souza</surname><given-names>C. P. E.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Kari</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Machine learning using intrinsic genomic signatures for rapid classification of novel pathogens: COVID-19 case study.</article-title><source><italic toggle="yes">PLoS One</italic></source><volume>15</volume>:<issue>e0232391</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0232391</pub-id><pub-id pub-id-type="pmid">32330208</pub-id><pub-id pub-id-type="pmcid">PMC7182198</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratha</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>G. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Haritaki (Chebulic myrobalan) and its varieties.</article-title><source><italic toggle="yes">Ayu</italic></source><volume>34</volume><fpage>331</fpage>&#8211;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.4103/0974-8520.123139</pub-id><pub-id pub-id-type="pmid">24501534</pub-id><pub-id pub-id-type="pmcid">PMC3902605</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Prasanna</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Valsala Gopalakrishnan</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronaviruses pathogenesis, comorbidities and multi-organ damage - a review.</article-title><source><italic toggle="yes">Life Sci.</italic></source><volume>255</volume>:<issue>117839</issue>. <pub-id pub-id-type="doi">10.1016/j.lfs.2020.117839</pub-id><pub-id pub-id-type="pmid">32450165</pub-id><pub-id pub-id-type="pmcid">PMC7243768</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oechsle</surname><given-names>O.</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>395</volume><fpage>e30</fpage>&#8211;<lpage>e31</lpage>.<pub-id pub-id-type="pmid">32032529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30304-4</pub-id><pub-id pub-id-type="pmcid">PMC7137985</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Menapace</surname><given-names>W.</given-names></name><name name-style="western"><surname>Oei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luijten</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Saltori</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Deep learning for classification and localization of COVID-19 markers in point-of-care lung ultrasound.</article-title><source><italic toggle="yes">IEEE Trans. Med. Imaging</italic></source><volume>39</volume><fpage>2676</fpage>&#8211;<lpage>2687</lpage>. <pub-id pub-id-type="doi">10.1109/tmi.2020.2994459</pub-id><pub-id pub-id-type="pmid">32406829</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Maity</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Inferring the genetic variability in Indian SARS-CoV-2 genomes using consensus of multiple sequence alignment techniques.</article-title><source><italic toggle="yes">Infect. Genet. Evol.</italic></source><volume>85</volume>:<issue>104522</issue>. <pub-id pub-id-type="doi">10.1016/j.meegid.2020.104522</pub-id><pub-id pub-id-type="pmid">32889094</pub-id><pub-id pub-id-type="pmcid">PMC7462517</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saiyad Musthafa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asgari</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Kurian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elumalai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jawahar Ali</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Paray</surname><given-names>B. A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Protective efficacy of <italic toggle="yes">Mucuna pruriens</italic> (L.) seed meal enriched diet on growth performance, innate immunity, and disease resistance in <italic toggle="yes">Oreochromis mossambicus</italic> against <italic toggle="yes">Aeromonas hydrophila</italic>.</article-title><source><italic toggle="yes">Fish Shellfish Immunol.</italic></source><volume>75</volume><fpage>374</fpage>&#8211;<lpage>380</lpage>. <pub-id pub-id-type="doi">10.1016/j.fsi.2018.02.031</pub-id><pub-id pub-id-type="pmid">29458093</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samaddar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gadepalli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nag</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>The enigma of low COVID-19 fatality rate in India.</article-title><source><italic toggle="yes">Front. Genet.</italic></source><volume>11</volume>:<issue>854</issue>. <pub-id pub-id-type="doi">10.3389/fgene.2020.00854</pub-id><pub-id pub-id-type="pmid">32849833</pub-id><pub-id pub-id-type="pmcid">PMC7399343</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senior</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jumper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sifre</surname><given-names>L.</given-names></name><name name-style="western"><surname>Green</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Improved protein structure prediction using potentials from deep learning.</article-title><source><italic toggle="yes">Nature</italic></source><volume>577</volume><fpage>706</fpage>&#8211;<lpage>710</lpage>.<pub-id pub-id-type="pmid">31942072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1923-7</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaffer</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>15 drugs being tested to treat COVID-19 and how they would work.</article-title><source><italic toggle="yes">Nat. Med.</italic></source><pub-id pub-id-type="doi">10.1038/d41591-020-00019-9</pub-id><comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">32415251</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahid</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kalayanamitra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mcclafferty</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kepko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramgobin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19 and older adults: what we know.</article-title><source><italic toggle="yes">J. Am. Geriatr. Soc.</italic></source><volume>68</volume><fpage>926</fpage>&#8211;<lpage>929</lpage>.<pub-id pub-id-type="pmid">32255507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.16472</pub-id><pub-id pub-id-type="pmcid">PMC7262251</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>U. K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>A. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Medicinal attributes of major phenylpropanoids present in cinnamon.</article-title><source><italic toggle="yes">BMC Complement Altern. Med.</italic></source><volume>16</volume>:<issue>156</issue>. <pub-id pub-id-type="doi">10.1186/s12906-016-1147-4</pub-id><pub-id pub-id-type="pmid">27245453</pub-id><pub-id pub-id-type="pmcid">PMC4888509</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheahan</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Leist</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Won</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>11</volume>:<issue>222</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-13940-6</pub-id><pub-id pub-id-type="pmcid">PMC6954302</pub-id><pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C. T.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X. J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W. Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z. L.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Evaluation of analgesic and anti-inflammatory activities of <italic toggle="yes">Rubia cordifolia</italic> L. by spectrum-effect relationships.</article-title><source><italic toggle="yes">J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.</italic></source><volume>1090</volume><fpage>73</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.jchromb.2018.05.021</pub-id><pub-id pub-id-type="pmid">29793098</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Review of artificial intelligence techniques in imaging data acquisition, segmentation and diagnosis for COVID-19.</article-title><source><italic toggle="yes">IEEE Rev. Biomed. Eng.</italic></source><pub-id pub-id-type="doi">10.1109/RBME.2020.2987975</pub-id><comment>[Epub ahead of print]</comment>.<pub-id pub-id-type="pmid">32305937</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D. U.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Macelignan attenuated allergic lung inflammation and airway hyper-responsiveness in murine experimental asthma.</article-title><source><italic toggle="yes">Life Sci.</italic></source><volume>92</volume><fpage>1093</fpage>&#8211;<lpage>1099</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2013.04.010</pub-id><pub-id pub-id-type="pmid">23643632</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirole</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Shirole</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Saraf</surname><given-names>M. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Embelia ribes ameliorates lipopolysaccharide-induced acute respiratory distress syndrome.</article-title><source><italic toggle="yes">J. Ethnopharmacol.</italic></source><volume>168</volume><fpage>356</fpage>&#8211;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2015.03.009</pub-id><pub-id pub-id-type="pmid">25818695</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Impact of COVID-19 and comorbidities on health and economics: focus on developing countries and India.</article-title><source><italic toggle="yes">Diabetes Metab. Syndr.</italic></source><volume>14</volume><fpage>1625</fpage>&#8211;<lpage>1630</lpage>. <pub-id pub-id-type="doi">10.1016/j.dsx.2020.08.032</pub-id><pub-id pub-id-type="pmid">32891011</pub-id><pub-id pub-id-type="pmcid">PMC7451213</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivasankarapillai</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Rahdar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sobha</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Mitropoulos</surname><given-names>A. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>On facing the SARS-Cov-2 (COVID-19) with combination of nanomaterials and medicine: possible strategies and first challenges.</article-title><source><italic toggle="yes">Nanomaterials (Basel)</italic></source><volume>10</volume>:<issue>852</issue>. <pub-id pub-id-type="doi">10.3390/nano10050852</pub-id><pub-id pub-id-type="pmcid">PMC7712148</pub-id><pub-id pub-id-type="pmid">32354113</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sluimer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schilham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prokop</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Ginneken</surname><given-names>B.</given-names></name></person-group> (<year>2006</year>). <article-title>Computer analysis of computed tomography scans of the lung: a survey.</article-title><source><italic toggle="yes">IEEE Trans. Med. Imaging</italic></source><volume>25</volume><fpage>385</fpage>&#8211;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1109/tmi.2005.862753</pub-id><pub-id pub-id-type="pmid">16608056</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spinelli</surname><given-names>F. R.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gadina</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.</article-title><source><italic toggle="yes">Sci. Immunol.</italic></source><volume>5</volume>:<issue>eabc5367</issue>. <pub-id pub-id-type="doi">10.1126/sciimmunol.abc5367</pub-id><pub-id pub-id-type="pmid">32385052</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sra</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Use of Face Masks in COVID-19.</article-title><source><italic toggle="yes">Indian J. Pediatr.</italic></source><volume>87</volume>:<issue>553</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12098-020-03316-w</pub-id><pub-id pub-id-type="pmcid">PMC7214229</pub-id><pub-id pub-id-type="pmid">32394156</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srinivasa Rao</surname><given-names>A. S. R.</given-names></name><name name-style="western"><surname>Vazquez</surname><given-names>J. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Identification of COVID-19 can be quicker through artificial intelligence framework using a mobile phone-based survey when cities and towns are under quarantine.</article-title><source><italic toggle="yes">Infect. Control Hosp. Epidemiol.</italic></source><volume>47</volume><fpage>826</fpage>&#8211;<lpage>830</lpage>. <pub-id pub-id-type="doi">10.1017/ice.2020.61</pub-id><pub-id pub-id-type="pmcid">PMC7200852</pub-id><pub-id pub-id-type="pmid">32122430</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stebbing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oechsle</surname><given-names>O.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19: combining antiviral and anti-inflammatory treatments.</article-title><source><italic toggle="yes">Lancet Infect. Dis.</italic></source><volume>20</volume><fpage>400</fpage>&#8211;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(20)30132-8</pub-id><pub-id pub-id-type="pmid">32113509</pub-id><pub-id pub-id-type="pmcid">PMC7158903</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tay</surname><given-names>M. Z.</given-names></name><name name-style="western"><surname>Poh</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Macary</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>L. F. P.</given-names></name></person-group> (<year>2020</year>). <article-title>The trinity of COVID-19: immunity, inflammation and intervention.</article-title><source><italic toggle="yes">Nat. Rev. Immunol.</italic></source><volume>20</volume><fpage>363</fpage>&#8211;<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-0311-8</pub-id><pub-id pub-id-type="pmid">32346093</pub-id><pub-id pub-id-type="pmcid">PMC7187672</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ting</surname><given-names>D. S. W.</given-names></name><name name-style="western"><surname>Carin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dzau</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T. Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Digital technology and COVID-19.</article-title><source><italic toggle="yes">Nat. Med.</italic></source><volume>26</volume><fpage>459</fpage>&#8211;<lpage>461</lpage>.<pub-id pub-id-type="pmid">32284618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0824-5</pub-id><pub-id pub-id-type="pmcid">PMC7100489</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiwari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design.</article-title><source><italic toggle="yes">J. Clin. Virol.</italic></source><volume>128</volume>:<issue>104441</issue>. <pub-id pub-id-type="doi">10.1016/j.jcv.2020.104441</pub-id><pub-id pub-id-type="pmid">32425659</pub-id><pub-id pub-id-type="pmcid">PMC7227581</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>Y. F.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Yarmishyn</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y. T.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A review of SARS-CoV-2 and the ongoing clinical trials.</article-title><source><italic toggle="yes">Int. J. Mol. Sci.</italic></source><volume>21</volume>:<issue>2657</issue>. <pub-id pub-id-type="doi">10.3390/ijms21072657</pub-id><pub-id pub-id-type="pmid">32290293</pub-id><pub-id pub-id-type="pmcid">PMC7177898</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urashima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akutsu</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>BCG vaccination and mortality of COVID-19 across 173 countries: an ecological study.</article-title><source><italic toggle="yes">Int. J. Environ. Res. Public Health</italic></source><volume>17</volume>:<issue>5589</issue>. <pub-id pub-id-type="doi">10.3390/ijerph17155589</pub-id><pub-id pub-id-type="pmcid">PMC7432030</pub-id><pub-id pub-id-type="pmid">32756371</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Ginneken</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ter Haar Romeny</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Viergever</surname><given-names>M. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Computer-aided diagnosis in chest radiography: a survey.</article-title><source><italic toggle="yes">IEEE Trans. Med. Imaging</italic></source><volume>20</volume><fpage>1228</fpage>&#8211;<lpage>1241</lpage>. <pub-id pub-id-type="doi">10.1109/42.974918</pub-id><pub-id pub-id-type="pmid">11811823</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viscusi</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Eimer</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Shaffer</surname><given-names>R. E.</given-names></name></person-group> (<year>2009</year>). <article-title>Evaluation of five decontamination methods for filtering facepiece respirators.</article-title><source><italic toggle="yes">Ann. Occup. Hyg.</italic></source><volume>53</volume><fpage>815</fpage>&#8211;<lpage>827</lpage>.<pub-id pub-id-type="pmid">19805391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annhyg/mep070</pub-id><pub-id pub-id-type="pmcid">PMC2781738</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>S.a.C</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>L. Y.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P. K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>397</volume><fpage>99</fpage>&#8211;<lpage>111</lpage>.<pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Drabek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Okba</surname><given-names>N. M. A.</given-names></name><name name-style="western"><surname>Van Haperen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>A human monoclonal antibody blocking SARS-CoV-2 infection.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>11</volume>:<issue>2251</issue>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16256-y</pub-id><pub-id pub-id-type="pmcid">PMC7198537</pub-id><pub-id pub-id-type="pmid">32366817</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>The establishment of reference sequence for SARS-CoV-2 and variation analysis.</article-title><source><italic toggle="yes">J. Med. Virol.</italic></source><volume>92</volume><fpage>667</fpage>&#8211;<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25762</pub-id><pub-id pub-id-type="pmid">32167180</pub-id><pub-id pub-id-type="pmcid">PMC7228400</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Prior-attention residual learning for more discriminative COVID-19 screening in CT images.</article-title><source><italic toggle="yes">IEEE Trans. Med. Imaging</italic></source><volume>39</volume><fpage>2572</fpage>&#8211;<lpage>2583</lpage>. <pub-id pub-id-type="doi">10.1109/tmi.2020.2994908</pub-id><pub-id pub-id-type="pmid">32730210</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.</article-title><source><italic toggle="yes">Cell Res.</italic></source><volume>30</volume><fpage>269</fpage>&#8211;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmid">32020029</pub-id><pub-id pub-id-type="pmcid">PMC7054408</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A weakly-supervised framework for COVID-19 classification and lesion localization from chest CT.</article-title><source><italic toggle="yes">IEEE Trans. Med. Imaging</italic></source><volume>39</volume><fpage>2615</fpage>&#8211;<lpage>2625</lpage>. <pub-id pub-id-type="doi">10.1109/tmi.2020.2995965</pub-id><pub-id pub-id-type="pmid">33156775</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wax</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Christian</surname><given-names>M. D.</given-names></name></person-group> (<year>2020</year>). <article-title>Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients.</article-title><source><italic toggle="yes">Can. J. Anesth.</italic></source><volume>67</volume><fpage>568</fpage>&#8211;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1007/s12630-020-01591-x</pub-id><pub-id pub-id-type="pmid">32052373</pub-id><pub-id pub-id-type="pmcid">PMC7091420</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Leibowitz</surname><given-names>J. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Coronavirus pathogenesis.</article-title><source><italic toggle="yes">Adv. Virus Res.</italic></source><volume>81</volume><fpage>85</fpage>&#8211;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-12-385885-6.00009-2</pub-id><pub-id pub-id-type="pmid">22094080</pub-id><pub-id pub-id-type="pmcid">PMC7149603</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D. X.</given-names></name></person-group> (<year>2018</year>). <article-title>Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3.</article-title><source><italic toggle="yes">Virology</italic></source><volume>515</volume><fpage>165</fpage>&#8211;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2017.12.028</pub-id><pub-id pub-id-type="pmid">29294448</pub-id><pub-id pub-id-type="pmcid">PMC7112132</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.</article-title><source><italic toggle="yes">J. Biol. Chem.</italic></source><volume>279</volume><fpage>3197</fpage>&#8211;<lpage>3201</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.c300520200</pub-id><pub-id pub-id-type="pmid">14670965</pub-id><pub-id pub-id-type="pmcid">PMC7982343</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G. F.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.</article-title><source><italic toggle="yes">Lancet Infect. Dis.</italic></source><volume>21</volume><fpage>39</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Protective effects of ethyl acetate extracts of <italic toggle="yes">Rimulus cinnamon</italic> on systemic inflammation and lung injury in endotoxin-poisoned mice.</article-title><source><italic toggle="yes">Drug Chem. Toxicol.</italic></source><volume>42</volume><fpage>309</fpage>&#8211;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1080/01480545.2018.1509987</pub-id><pub-id pub-id-type="pmid">30257565</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Potdar</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Choudhary</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Nyayanit</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jadhav</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Full-genome sequences of the first two SARS-CoV-2 viruses from India.</article-title><source><italic toggle="yes">Indian J. Med. Res.</italic></source><volume>151</volume><fpage>200</fpage>&#8211;<lpage>209</lpage>.<pub-id pub-id-type="pmid">32242873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijmr.IJMR_663_20</pub-id><pub-id pub-id-type="pmcid">PMC7258756</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsuyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>J. I.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay.</article-title><source><italic toggle="yes">Antimicrob. Agents Chemother.</italic></source><volume>60</volume><fpage>6532</fpage>&#8211;<lpage>6539</lpage>. <pub-id pub-id-type="doi">10.1128/aac.01043-16</pub-id><pub-id pub-id-type="pmid">27550352</pub-id><pub-id pub-id-type="pmcid">PMC5075056</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Composition and biological activities of hydrolyzable tannins of fruits of <italic toggle="yes">Phyllanthus emblica</italic>.</article-title><source><italic toggle="yes">J. Agric. Food Chem.</italic></source><volume>62</volume><fpage>529</fpage>&#8211;<lpage>541</lpage>. <pub-id pub-id-type="doi">10.1021/jf404703k</pub-id><pub-id pub-id-type="pmid">24369850</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</article-title><source><italic toggle="yes">Clin. Infect Dis.</italic></source><volume>71</volume><fpage>732</fpage>&#8211;<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id><pub-id pub-id-type="pmid">32150618</pub-id><pub-id pub-id-type="pmcid">PMC7108130</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>The pathogenesis and treatment of the &#8216;Cytokine Storm&#8217; in COVID-19.</article-title><source><italic toggle="yes">J. Infect.</italic></source><volume>80</volume><fpage>607</fpage>&#8211;<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.037</pub-id><pub-id pub-id-type="pmid">32283152</pub-id><pub-id pub-id-type="pmcid">PMC7194613</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Genotyping coronavirus SARS-CoV-2: methods and implications.</article-title><source><italic toggle="yes">Genomics</italic></source><volume>112</volume><fpage>3588</fpage>&#8211;<lpage>3596</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygeno.2020.04.016</pub-id><pub-id pub-id-type="pmid">32353474</pub-id><pub-id pub-id-type="pmcid">PMC7184998</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Q. L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z. J.</given-names></name><name name-style="western"><surname>Gou</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G. F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019.</article-title><source><italic toggle="yes">J. Infect Dis.</italic></source><volume>222</volume><fpage>38</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiaa228</pub-id><pub-id pub-id-type="pmid">32348485</pub-id><pub-id pub-id-type="pmcid">PMC7197534</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical characteristics of 82 cases of death from COVID-19.</article-title><source><italic toggle="yes">PLoS One</italic></source><volume>15</volume>:<issue>e0235458</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0235458</pub-id><pub-id pub-id-type="pmid">32645044</pub-id><pub-id pub-id-type="pmcid">PMC7347130</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Penninger</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Slutsky</surname><given-names>A. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.</article-title><source><italic toggle="yes">Intensive Care Med.</italic></source><volume>46</volume><fpage>586</fpage>&#8211;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-05985-9</pub-id><pub-id pub-id-type="pmid">32125455</pub-id><pub-id pub-id-type="pmcid">PMC7079879</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Devshilt</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>An</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Fennel main constituent, transanethole treatment against LPSinduced acute lung injury by regulation of Th17/Treg function.</article-title><source><italic toggle="yes">Mol. Med. Rep.</italic></source><volume>18</volume><fpage>1369</fpage>&#8211;<lpage>1376</lpage>.<pub-id pub-id-type="pmid">29901094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2018.9149</pub-id><pub-id pub-id-type="pmcid">PMC6072219</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y. F. B.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients.</article-title><source><italic toggle="yes">Natl. Sci. Rev.</italic></source><volume>7</volume><fpage>998</fpage>&#8211;<lpage>1002</lpage>. <pub-id pub-id-type="doi">10.1093/nsr/nwaa041</pub-id><pub-id pub-id-type="pmcid">PMC7108005</pub-id><pub-id pub-id-type="pmid">34676125</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>